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ABSTRACT 
 
There are different conformational states of proteins characterized by different Gibbs 
free energy levels, manifested in folding-unfolding dynamics, for example. Recently, a set of 
protein states, which require relatively small amount of folding energies, emerged as subjects of 
intensive research, and proteins or regions characterized by the presence of these states have 
been termed as ‘Intrinsically Disordered Proteins’ (IDP) and ‘Intrinsically Disordered Protein 
Regions’ (IDPR), respectively. Predisposition for intrinsic disorder of a query protein is encoded 
in its amino acid sequence and composition, and can be rather accurately predicted using 
several intrinsic disorder algorithms. Since pathology of many human diseases can be driven by 
proteins characterized by high intrinsic disorder scores, research on various disease-associated 
proteins is often started with the analysis of their intrinsic disorder propensities. In this work, I 
utilized computational approaches based on the concept of intrinsic disorder to address three 
health-related issues. To this end, I developed a novel computational platform for disorder-
based drug discovery and applied this tool for finding inhibitors of the cancer-related MBD2-
NuRD complex, utilized molecular dynamic simulations to explain the effects of mutations on the 
functionality of the X-linked protoporphyria-related protein ALAS, and used bioinformatics tools 
to examine the effects of cardiomyopathy-related mutations in cardiac troponin.   
Since the complex between the Methyl-CpG-binding domain protein 2 (MBD2) and the 
Nucleosome Remodeling Deacetylase complex (NuRD) specifically binds to the mCpG-island 
and blocks tumor suppressor gene expression, finding an inhibitor of this MBD2-NuRD complex 
is hypothesized to be important for the development of novel anti-cancer drugs. I found that the 
xii 
 
site, which is responsible for the MBD2 interaction with the transcriptional repressor p66-α 
(p66α, which is a part of the NuRD complex), is characterized by a specific disorder-to-order 
transition pattern, this pattern showed a remarkable similarity to the disorder-to-order pattern of 
the Myc transcription factor binding site for the Max transcription factor. Importantly, several 
inhibitors of the Myc-Max interaction targeting the disorder-to-order transition site of Myc were 
previously described. By applying molecular docking at the disorder-to-order transition site of 
MBD2, two compounds were identified and further evaluated through molecular dynamics 
simulations. Anti-leukemia and anti-metastasis effectiveness of these compounds was 
demonstrated in dedicated in vitro and in vivo experiments conducted by our collaborators.  
In relation to the defective protein associated with the X-linked protoporphyria (XLPP), 
the hepta-variant of mouse erythroid 5-aminolevulinate synthase (mALAS2), previously shown 
to be characterized by a remarkable acceleration of the reaction rate, was investigated through 
molecular dynamics simulations. In this study, a loop to β-strand transition was observed, and 
this observation was crucial for a better understanding of the previously described rate-
enhancing effects of seven simultaneous variations in the active loop site of this protein.  
Finally, a wide spectrum of bioinformatics tools was applied to carefully analyze a 
potential role of intrinsic disorder in a set of cardiomyopathy-related mutations in the 
components of human cardiac troponin. This analysis revealed that, in comparison with the wild 
type troponin, chains containing the disease-associated mutations were typically characterized 
by a local decrease in intrinsic disorder propensity. These mutations affected some disorder-
based protein-protein interaction sites and caused remarkable rearrangements of the complex 
pattern of post-translational modifications. 
Therefore, this work illustrates that inclusion of the protein intrinsic disorder analysis into 
the arsenal of techniques used by the biomedical researchers represents an important and 
promising approach that provides novel inputs for the better understanding of protein behavior 
xiii 
 
in relation to human disease at the molecular level. Techniques and methods developed and 
utilized in this study will significantly contribute to future biomedical research. 
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CHAPTER 1. PROTEIN STRUCTURE, FUNCTION, FOLDING, AND INTRINSIC DISORDER 
 
1.1 Background 
1.1.1 Anfinsen’s Dogma and Protein Structure Determining Experiments 
 From the traditional biochemistry viewpoint, it was believed and verified experimentally 
that proteins have unique structures and function according to their specific structural features. 
Dr. Christian B. Anfinsen had shown that function of a chemically unfolded protein can be 
spontaneously restored after denaturant elimination, and he earned a Nobel Prize based on 
these findings [2, 3]. In the course of his studies, he dissolved a common enzyme, RNase, in a  
strong denaturant (8M urea) in the presence of the reducing agent β-mercaptoethanol. Under 
these conditions, all disulfide bonds were reduced and the protein was completely unfolded, as 
manifested by the lack of any specific structure in RNase and the complete lack of enzymatic 
activity. However, after elimination of the denaturant and the reducing agent, the activity of the 
RNase was completely restored [2]. From these experiments, an important principle was 
derived, namely, the protein amino acid sequence determines an unique 3D structure that 
defines functionality. This is called the ‘Anfinsen’s Dogma’. 
X-ray crystallography, Nuclear Magnetic Resonance (NMR) spectroscopy and cryo-
electron microscopy (cryo-EM) focuses on determining the structural characteristics of proteins. 
In cyclotrons, accelerated electrons emit X-rays, and diffraction occurs as a result of collisions 
between the X-ray and the protein crystal. After the diffraction pattern is interpreted by Fourier 
transformation, scientists can characterize the structure in detail. In the case of NMR 
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spectroscopy, molecules are exposed to an external magnetic field. The atoms interact with this 
magnetic field according to their magnetic spin characteristics (quantum number) giving rise to 
specific patterns in the NMR spectrum that can be interpreted to decipher protein structure. In 
cryo-EM, a frozen sample is studied at cryogenic temperatures by means of transmission 
electron microscopy (TEM), that uses a beam of electrons instead of light to determine the 
morphological and structural peculiarities of specimens in their native environment without using 
any staining or fixation. These techniques are very useful tools to study structural features of 
proteins. However, if the molecule is very flexible, it represents a serious challenge for atom-
level structural characterization. 
Anfinsen’s dogma, X-ray crystallography and NMR methods (and more recently cryo-
EM) are still standard for protein structure research. However, a better understanding of 
functional proteins forced scientists to consider the biological importance of flexible regions and 
entirely disordered proteins. This field of protein science is actively investigated nowadays and 
known as the ‘Protein Intrinsic Disorder’ phenomenon. 
 
1.1.2 Discovery of the Partially (Un)folded Protein State (Molten Globule) and 
Understanding of Protein Folding Dynamics 
 The possibility of a protein to form a partially (un)folded state was firstly proposed by Dr. 
Oleg B. Ptitsyn in 1973 [4, 5]. This idea was a serious challenge toward the previous year 
(1972) Nobel Prize given for the Anfinsen’s dogma. In subsequent years, Ptitsyn’s group studied 
structural properties of the partially (un)folded state of a protein induced by various means [6, 7]. 
Through these studies that utilized a wide spectrum of biophysical techniques sensitive to the 
different levels of protein structural organization, his group was able to discover novel properties 
of partially (un)folded proteins, such as their high overall compactness, great interior density, 
high secondary structure content, lack of specific structure around aromatic amino acid residues, 
high degree of conformational fluctuations, and lack of a melting temperature. One of the 
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proteins analyzed by Ptitsyn’s group was α-lactalbumin, which was shown to contain an 
intermediate state characterized by the simultaneous presence of 'native-like' and 'unfolded-like' 
properties [7]. Later, another group in Japan described similar properties for another small 
globular protein, cytochrome c, and they named this protein state 'Molten Globule' [8]. 
 Molten globule state discovery expanded the understanding of protein folding and 
dynamics [9]. In fact, prior to the discovery of the molten globule, it was assumed that protein 
folding dynamics could be described by a series of equations shown below, which considers 
only folded and unfolded states:  
 
 
 
 , 
where, [Unfolded] is the concentration of unfolded protein in equilibrium, [Folded] is the 
concentration of folded protein in equilibrium, kfolding is the folding reaction rate constant, kunfolding 
is the unfolding reaction rate constant, Keq is the equilibrium constant, ΔG is the Gibbs free 
energy, R is  the universal gas constant (8.314 J·K-1·mol-1), and T is the temperature. 
 However, protein folding does not occur in a simple manner. Dr. Cyrus Levinthal argued 
that in going from the unforlded to folded state, a simple random search for a unique folded form 
of a protein within a vast conformational space of all allowed configurations of a polypeptide 
chain would take an infinitely long time, whereas a natural protein can fold fast and efficiently. 
This observation is called ‘Levinthal’s Paradox’ [10]. Three folding models were proposed after 
Dr. Levinthal’s idea [11]: framework (diffusion-collision) model [4, 12-14], nucleation model [15, 
16], and hydrophobic-collapse model [9, 17]. The framework (diffusion-collision) model 
suggested a folding mechanism where the elements of protein secondary structures are formed 
first and diffused until these secondary structure elements collide to form the tertiary structure [4, 
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12-14]. The nucleation-condensation model supports the idea of simultaneous formation of 
secondary and tertiary structures of the protein, where some neighboring residues are able to 
form a secondary or super-secondary structure element that functions as a nucleus, and tertiary 
structure collapses onto this nucleus [15, 16]. The hydrophobic-collapse model highlights the 
importance of hydrophobicity for the formation and maintenance of protein structure [9, 17]. 
According to this model, hydrophobic side chains cause fast protein collapse, the resulting 
collapsed conformations are characterized by limited internal structure, but specific secondary 
structure elements and unique tertiary contacts are developed inside these collapsed 
intermediates, eventually leading to the formation of a native protein structure [9, 17]. Discovery 
of numerous molten globules and other partially folded intermediates in experimental settings 
for various proteins supported the ideas of the frame-work model, and the hydrophobic-collapse 
model [11]. However, the nucleation-condensation model cannot explain the existence of many 
intermediate states [11]. Therefore, the discovery of the molten globule and other partially folded 
intermediates played an important role in finding the proper protein folding model. 
 
1.1.3 Novel Viewpoint of Protein Classification According to Their Folding Status 
 The ability to evaluate the Gibbs free energy from protein folding dynamics broadened 
insights into protein classification. Because different energy values reflect diverse protein folding 
states, if ΔG is given, then the protein conformation can be classified according to its folding 
status (Figure 1.1). The folding status of a functional protein can be classified into different 
categories according to different viewpoints (Figure 1.2). As shown in Figure 1.2A, functional 
proteins can be simply grouped into three different categories: ordered (folded), molten globule-
like, and random coil (unfolded). However, as many scientists have discovered while analyzing 
structural properties of different functional proteins, the pre-molten globule-like conformation is 
nowadays considered as a new category of protein folding status [18]. 
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Figure 1.1 Energy funnel model reflects folding status of a protein. Energy funnel 
indicates that the large ensemble of diverse unfolded states with high energy (see top plane 
in the plot) can enter the native (folded) state with the lowest energy. Reprinted from original 
article [19], under copyright permission by Copyright Clearance Center (Appendix A). 
  
 
Figure 1.2 Functional protein folding status classifications. A Traditional classification, B 
Novel classification. Reprinted from original article [18], under copyright permission by 
Copyright Clearance Center (Appendix A). 
  
 The molten globule state is characterized by several specific features [20]. This protein 
form is compact and contains well-developed secondary structure, but has no tertiary structure. 
The high degree of compactness is due to the hydrophobic collapse, which ensures the 
presence of a dense hydrophobic core that is ill-protected from the solvent due to the lack of 
stable tertiary contacts.This state is observed for many globular proteins in mild denaturing 
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conditions. Also, many intrinsically disordered proteins can be considered as native molten 
globules.  
The pre-molten globule state is structurally distinguished from both the molten globule 
and the coil-like states of a protein [18, 20-22]. The protein molecule in this state has less 
ordered secondary structure than the molten globule, and it does not have tertiary structure. It 
has larger compactness than the unfolded state, but is less compact than the molten globule. In 
addition, although the pre-molten globule does not have a globular structure, it still can bind the 
fluorescent dye, 8-anilinonaphthalene-1-sulphonate (ANS), but not as efficient as the molten 
globule does. Again, similar to molten globule, the pre-molten globule-like conformations can be 
found for foldable ordered proteins in the presence of some mild denaturing conditions. 
However, some functional proteins in their native forms have the properties of the pre-molten 
globules.  
Discoveries of various folding intermediates (molten globule, and pre-molten globule) 
have strengthen the importance of factors contributing to protein folding-unfolding [23-26]. They 
also open new ways of looking on protein functionality. In fact, although the existence of folding 
intermediates was emphasized in 1973 [2, 3], it took more than 25 years to recognize that such 
partially folded forms of a polypeptide chain are not only crucial stepping stones of protein 
folding that are transiently populated during the folding process that eventually brings unique 
3D-structure to a newly synthesized polypeptide chain, but might be present in a living cell as 
thermodynamically stable and functional entities, now known as intrinsically disordered proteins 
[23-26].  
Obviously, because of the lack of unique 3D-structures such partially folded proteins are 
not amenable for high resolution structural characterization by X-ray crystallography. Although 
detailed structural information can be provided for such partially folded polypeptide chains by 
NMR, this approach too has limitations and restrictions. Therefore, often times researchers rely 
on various computational methods to study structural and dynamic peculiarities of the unfolded 
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state [27-48]. Furthermore, as it was mentioned, it is recognized now that partially folded forms 
are not only folding intermediates of ordered proteins that accumulate under mild denaturing 
conditions or are transiently populated during protein folding, but might be the final and 
functional states of some proteins, thereby emphasizing structural heterogeneity of intrinsically 
disordered proteins. 
 
1.1.4 Degrees of Unfolding and Protein Intrinsic Disorder 
 According to this viewpoint, functionality can be related not only to ordered proteins with 
well-defined 3D-structures, but also to partially folded or even completely unfolded proteins that 
cannot be easily characterized by X-ray crystallography or NMR. These biologically active 
proteins without specific 3D-structures are known as ‘Intrinsically Disordered Proteins’ (IDP). In 
the same line of thought, highly dynamic protein parts are named ‘Intrinsically Disordered 
Protein Regions’ (IDPR). It is now recognized now that the highly dynamic nature of IDP or 
IDPR is engendered from their specific amino acid compositions, where physico-chemical 
properties of each amino acid has a specific relation to the dynamic properties of IDPs or IDPRs 
[49] (Figure 1.3). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3 Amino acid level of protein intrinsic disorder. Reprinted from original article 
[49], under copyright permission by Copyright Clearance Center (Appendix A). 
 
Therefore, although different degrees of unfolding can be induced in an ordered globular 
protein by changes in its environment, varying levels of disorderedness in IDPs and IDPRs are 
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observed under the physiological conditions and are determined by the peculiarities of amino 
acid sequences of these proteins and regions. Another important consideration of the intrinsic 
disorder phenomenon is related to the discovery of a peculiar relation of various IDPs/IDPRs to 
human disease. In fact, numerous IDPs were shown to be related to the pathogenesis of 
diseases such as allergies, amyloidoses, cancer, cardiovascular disease, diabetes, genetic 
diseases, and neurodegenerative diseases, as well as are commonly found in viral proteomes 
[27-48]. Furthermore, because their broad engagement in pathogenesis of human diseases, 
IDPs/IDPRs are considered as promising, but challenging drug targets [50-53]. One should also 
keep in mind that IDPs/IDPRs with various levels and depth of disorder are integrated in the 
new protein structure-function paradigm (Figure 1.2), where protein functionality can originate 
from different conformations and/or transitions between them. Finally, protein intrinsic disorder 
is considered now as an important factor that need to be taken into account in protein folding-
unfolding studies. Therefore, multiple computational algorithms were developed to investigate 
the nature and occurrence of intrinsic disorder in query proteins at the amino acid level. 
1.2 Computational Studies of Protein Structure and Dynamics 
1.2.1 Protein Intrinsic Disorder Prediction Algorithms (PONDR-VLXT, -VSL2, -FIT) 
 As described in previous sections (see sections 1.1.3, 1.1.4), because of experimental 
difficulties to study IDP or IDPR, scientists have made efforts to trace protein intrinsic disorder at 
the amino acid level using various computational tools. First generation intrinsic disorder 
algorithms depended on the comparison of experimental data and data deposited in the Protein 
Data Bank (PDB) [54-57]. A representative example of the first generation algorithm for 
prediction of intrinsic disorder is PONDR-VLXT [57]. This predictor utilized different features to 
each amino acid, and was based on a connection of intrinsic disorder with regions of missing 
electron density in a small number of PDB files how X-ray crystallography and on an even 
smaller number of NMR structures [54, 55]. Subsequent efforts were devoted to a better 
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understanding of the regional properties of proteins, such as, N- or C-terminal regions and 
internal regions [56]. Finally, outputs of the developed computational tools for several proteins 
were compared with experimental structural characterizations by X-ray crystallography, NMR, 
and circular dichroism (CD) in order to analyze correlations between prediction and experiment 
[57]. 
The second generation of disorder predictors were based on combining the first 
generation predictors. This type of predictive algorithm is known as a meta-predictor. A 
representative second generation algorithm for the prediction of protein intrinsic disorder is 
PONDR-VSL2 [58-60]. Rather good agreement was found between the results of disorder 
prediction and actual structure of proteins used as targets of structure prediction in CASP5 [61]. 
This observation served as a strong motivation for the development of more accurate algorithms 
for prediction of intrinsic disorder that were included in the CASP6 competition. In one case, 
developers elaborated approaches for the prediction of the intrinsic disorder at two levels, for 
long regions (> 30 amino acids), and for short regions (≤ 30 amino acids) [58]. For evaluation of 
the presence of long disordered regions, they combined several pre-existing predictors including 
PONDR-VLXT. For the prediction of short regions (≤ 30 amino acids), they developed a specific 
predictor based on experimental data. After combining these two predictors, they created a new 
algorithm that was named PONDR-VSL1 [58]. The importance of this work was illustrated by the 
fact that the meta-predictor worked well for the protein intrinsic disorder prediction. Next, the 
same group of researchers evaluated the importance of evolutionary conservation at the amino 
acid sequence level [59]. Adding evolutionary considerations to the PONDR-VSL1 algorithm led 
to a slight improvement of the predictor accuracy, and the resulting algorithm was named 
PONDR-VSL2. A methodological important update of PONDR-VSL2 was its support vector 
machine integration instead of logistic regression, which was used in the PONDR-VSL1 
development [60]. One should note that PONDR-VSL2 continues to be one of the more 
accurate algorithms that shows relatively better performance than many other predictors. 
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The third generation of intrinsic disorder predictors is also a meta-predictor type, with 
PONDR-FIT serving as a representative example of the third generation [62]. It simply 
combined six different individual intrinsic disorder predictors, such as three members of the 
PONDR family, PONDR-VLXT, PONDR-VSL2, and PONDR-VL3 (a tool specifically developed 
for accurate prediction of long disordered regions), as well as three non-PONDR predictors. 
One of those is IUPred, which predicts intrinsic disorder according to folding energy calculation 
[63]. Other two predictors are characterized by utilizing charge-hydropathy calculation 
(FoldIndex) [64], and scaled disorder-order propensity determination (TopIDP) [65]. The 
importance of PONDR-FIT is that it used a set of rather orthogonal approaches and moved 
away from the common practice of working only with in-house tools (all members of the family 
PONDR family of intrinsic disorder predictors have been developed by the research group of Dr. 
Keith Dunker) and used algorithms developed by other research groups. Through utilization of 
various computational approaches and algorithms, diverse aspects of protein intrinsic disorder 
can be evaluated. 
 
1.2.2 Molecular Docking 
It is recognized that utilization of various computational means for evaluation of 
molecular properties represents an important contribution to the research related to human 
health. Molecular docking is a useful techniques to achieve this purpose. From the late 1970s, it 
was used as a key component of the structure-based drug discovery (SBDD) [66-68]. Since 
proteins are involved in diverse physiological and pathological processes, finding of specific 
modulators (inhibitors or activators) of targeted proteins is considered a good strategy to control 
physiological problems associated with disease. To successfully use the SBDD (which relies on 
the known 3D-structure of a target protein and structures of chemical compounds), molecular 
structure databases are required. The Protein Data Bank (PDB) provides crucial information on 
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molecular structures determined by X-ray crystallography or NMR [69], whereas  ZINC serves 
as an example of a database that provides structural information on numerous of chemical 
compounds [70]. 
Additionally, and importantly, molecular docking is required for sucssesful SBDD [68, 71-
73]. DOCK is a representative molecular docking software [71, 74, 75] that calculates binding 
energy scores from structures of given protein targets and ligands (Figure 1.4). 
 
Figure 1.4 Binding energy score calculation by DOCK. Reprinted from original article [76], 
under copyright permission by Copyright Clearance Center (Appendix A). (ΔGbind : Binding 
energy score, ΔGelec,interact : Electrostatic interaction energy, ΔGvdw,interact : van der 
Waals component of interaction energy, ΔGelec,L,solv : Ligand electrostatic solvation 
energy, ΔGnp,L,solv : Non-polar component of ligand solvation energy) 
 
Firstly, DOCK provides parameters of the target and the ligand. From a given set of 
parameters, the solvent accessible surface area is calculated [77]. This step is required to 
define the docking site. Then, an energy grid is constructed, and each grid point stores the 
electrostatic interaction energy [78-80]. Further polar solvation, and non-polar solvation energy 
calculations results are added to the electrostatic energy calculation [76]. Finally, DOCK ranks 
the ligands according to binding affinity calculation results. 
Due to the dramatic increase in computational power, lots of ligands could be evaluated 
to serve as potential inhibitors blocking certain protein activities. Corresponding libraries are 
constructed using numerous ligands, and library-based molecular docking is frequently used. 
Hence, molecular docking expands human ability to find a suitable drug candidate through 
computational calculations of molecular properties. 
1.2.3 Molecular Dynamics (MD) Simulation 
The beauty of computational research of protein behavior is perfectly illustrated by 
molecular dynamics simulation. The first article describing the MD simulation of a protein was 
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published in 1977, by Dr. Andrew J. McCammon as a first author [81]. Although it dealt with 
much shorter simulation times (9.2 ps) than nowadays, this work was a clear leap that opened 
new horizons in protein science.  
 
 
 
 
 
 
 
 
Figure 1.5 Force-field potential energy calculation (CHARMM). Reprinted from original 
article [82], under copyright permission by Copyright Clearance Center (Appendix A) 
 
Over the time, the technique has expanded much as computer power increased. MD 
simulations are performed through energy calculations, where the force-field provides potential 
energy. Atomic forces are derived from the potential energy [82-84]. Force-fields (such as, 
CHARMM) yield potential energies that are calculated from bonded and non-bonded energy 
terms according to the parameters [82, 84] (Figure 1.5). 
The bonded potential energy is evaluated from the bond vibrational potential energy, the 
angular potential energy, and the dihedral energy. Non-bonded potential energy is evaluated 
from the Coulombic electrostatic interaction energy and the van der Waals interaction energy 
(Lennard-Jones 6-12 term). After the bonded and non-bonded potential energies are summed 
up, a derivative is used to generate force. Because force equals mass times acceleration, the 
acceleration values can be calculated from the force. From the acceleration, the velocity and 
coordinates can be obtained through serial integration [85, 86]. 
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(where, F : Force, U : Potential energy, r : Coordinate vector, a : acceleration vector, v : velocity 
vector, m : mass, t : time) 
 Molecular dynamics simulations start with a energy minimization step. Energy 
minimization is required to set all atom positions close to the potential energy minimum position 
before any velocity assignment in the system. After the energy minimization step, the velocity is 
assigned according to given temperature using the below equation [87]. 
 
(where, KB : Boltzmann constant, T(t) : Temperature at time t, vi : velocity vector of atom i, N : 
Number of atoms in the system, m : mass, t : time) 
 Through serial heating steps with increased temperatures, the system can be prepared 
to be analyzed at a desired temperature (300 K, as an example). Once the system reaches the 
desired temperature, the system enters the equilibration phase in order to reach equilibrium. 
Position restraint force constants could be serially reduced during the equilibrations, thus atom 
positions are serially released to follow the force-field parameters. After equilibration, the system 
enters the production phase, during which the molecular dynamics is continuously calculated, 
and the subsequent analysis generates the meaning of the observed dynamics. 
 MD simulations played an important role in expanding the current understanding of 
protein behavior. In fact, through MD simulations of proteins, scientists can understand 
important details of structural characteristics based on physical chemistry theory. If MD 
simulation is used to analyze a system generated from molecular docking, it can contribute 
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important information needed for drug discovery. If MD simulation is applied to protein folding-
unfolding dynamics, it contributes to furthering scientific knowledge related to protein structure 
and function. Hence, MD simulation is an important technique, not only for fundamental science, 
but also for studies related to human health.  
1.3 Closing Remarks – Protein Intrinsic Disorder and Computational Research 
 Protein intrinsic disorder research continues to present a significant challenge for 
experimentalists utilizing tools specifically designed for protein structure analysis, because it 
deals with “invisible characteristics” of a polypeptide chain. The phenomenon is contributing 
significantly to the natural behavior of proteins. 44 years passed since introduction of the molten 
globule idea in 1973, and the developments of modern protein science combined with the 
dramatic growth in power of computer hardware have allowed people to better understand the 
universal nature of partially folded proteins and gain important knowledge on protein intrinsic 
disorder. Structural biology, biochemistry, computer science, bioinformatics, biophysical 
chemistry have evolved in such a way that we are getting closer to a better and more complete 
understanding of the most important biological molecules. Therefore, nowadays, computer-
based protein-related and protein-centric studies are contributing crucial knowledge related to 
human health. Computers can be now applied in any type of protein oriented molecular 
research. In fact, from intrinsic disorder prediction alone, the analyst can notice specific protein 
structural characteristics, because the propensity for protein intrinsic disorder is the summary of 
physic-chemical properties of protein related to its flexibility. The subsequent application of 
molecular docking and MD simulations clearly demonstrates the usefulness of the protein 
intrinsic disorder concept, and enhances the meaning of protein intrinsic disorder. 
 Chapter 2-4 describe the studies of several health-related systems. All the related 
projects have started with the protein intrinsic disorder predictions in proteins related to the 
human diseases and are followed by other computational tools as needed. 
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CHAPTER 2. MBD2-p66α INHIBITOR DISCOVERY 
 
Note to reader 
 Parts of this chapter were previously disclosed at a poster presentation session at the 
2016 Conference of the Genetics Society of America (Orlando, FL, USA Jul. 13-17, 2016), and 
have been reproduced under permission of Dr. Chul Geun Kim, who is a Professor at the 
Hanyang University in Seoul, South Korea (Appendix A, B). The wet lab experiments presented 
in this chapter were conducted in Dr. Kim’s lab. 
2.1 Introduction 
2.1.1 Methylated CpG (mCpG) island, MBD2–NuRD, and Inhibition Outcome 
mCpG island controls tumor suppressor gene expression, thus it is a possible target for 
the development of a new anti-cancer treatment strategy [88]. The NuRD complex is an 
epigenetic control factor that combines multiple proteins including MBD2 or MBD3. Because the 
NuRD complex binds only one of MBD2 or MBD3, it can be classified as MBD2-NuRD or 
MBD3-NuRD complex. MBD2-NuRD specifically binds to the mCpG island and blocks tumor 
suppressor gene expressions [89, 90]. The mCpG island binding capability of MBD2 was 
discovered in 1998, and the NuRD complex was discovered in 1999 [91, 92]. Subsequent 
experiments showed the possibility of complex formation between MBD2 and NuRD [93]. MBD2 
was further investigated due to its importance for mCpG island binding and its ability to control 
tumor suppressor gene expression [88]. The NuRD complex controls expression of various 
genes through epigenetic mechanisms, and it combines ATPase (CHD3/4), HDAC, MBD2 (or 
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MBD3), RBBP, MTA, and p66α/β [89, 90]. HDAC, RBBP, and MTA form the core of the NuRD 
complex that binds to the middle region of MBD2, whereas ATPase and p66α/β bind to the C-
terminal region of MBD2. The MBD domain is conserved among the MBD family proteins, and 
MBD2 and MDB3 have a common property to bind the NuRD complex due to their similar 
domain compositions [94].   
For MBD2-NuRD, the structure of the MBD2-p66α complex was studied using NMR [95]. 
Although a p66α mutation study was performed and a p66α-binding site of MBD2 was 
postulated in 2006 [96], the p66α-binding residues of MBD2 were not resolved. The 2011 NMR 
study discovered MBD2 residues involved in p66α binding [95]. Also, it clearly showed a coiled-
coil structure between MBD2 and p66α originated due to a disorder-to-order transition in the 
corresponding protein regions. Recently, the MBD2-binding site of NuRD core was defined 
through mutation studies [97]. This binding region was named MBD2idr due to its intrinsic 
disorder nature. When the R286E/L287A double mutation was introduced in MBD2, interactions 
beteween MBD2 and the NuRD core proteins was disrupted. Finally, the same double mutation 
led to induced expression of tumor suppressor genes. However, there was no study to resolve 
the inhibitor targeting p66α-binding site of MBD2. 
 
2.1.2 Myc-Max Inhibition 
A disorder-to-order transition disrupting Myc inhibitor, 10058-F4, was discovered in 2003 
[98]. Intrinsically disordered regions of proteins sometimes form a structure upon interaction with 
specific binding partners that could induce either order or intrinsic disorder. This mechanism is 
called binding-induced disorder-to-order transition [28], and Myc-Max binding serves as an 
illustrative example of such mechanism [99]. After discovery of 10058-F4, Follis et al. [100] were 
able to define the binding region of the MBD2 protein responsible for interaction with 10058-F4, 
and this binding site was located within the disorder-to-order transition region (MBD2 residues 
402-412) embedded inside the Max-binding site. The authors also studied structural changes in 
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MBD2 induced by 10058-F4, that were described in terms of the transition from unstructured 
elements to a structured α-helix, mimicking the disorder-to-order transition [100]. A molecular 
dynamics study defined favorable MBD2 residues within the 10058-F4 binding site (MBD2 402-
412), and Y402 was determined as the most favored MBD2 residue for 10058-F4 binding [101]. 
However, because these authors considered only the 402-412 region of MBD2 in their 
molecular dynamics simulation study, it was crucial to analyze the peculiarities of the 10058-F4 
binding behavior within the context of the full-length MBD2 protein. 
 
2.1.3 Research Purpose and Approach 
A MBD2-NuRD inhibitor has not been developed as of yet, even though MBD2-NuRD 
controls expression of important tumor suppressor genes [88]. Therefore, the objective of this 
project was to discover a novel anti-cancer drug candidate to target the MBD2-NuRD complex. 
To attain this objective, we tested the working hypothesis that inhibition of the interaction 
between MBD2 and p66α (which is a key component of the NuRD complex) would show anti-
cancer effectiveness. To test this working hypothesis, we applied a wide spectrum of in silico, in 
vitro, and in vivo methods. To find suitable chemical compounds, we first conducted molecular 
docking experiments that targeted the MBD2 disorder-to-order transition region, which also 
serves as an MBD2-p66α binding site. Then, to further evaluate several chemical compounds 
found in those docking experiments, we applied molecular dynamics simulations. In parallel, our 
collaborators performed various in vitro and in vivo tests where the anti-cancer potential of 
several candidates was analyzed. The expected outcomes of this aim were at least two-fold. 
First, the successful achievement of the proposed goals would contribute to the discovery of 
novel anti-cancer drug candidates. Second, the successful completion of this specific aim would 
contribute to the field of computer-aided drug discovery by its virtue of targeting specific 
molecular docking areas that are based on intrinsic disorder and therefore are characterized by 
a new biochemical background. These results therefore are a critical improvement of drug 
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discovery, because we are targeting protein regions with specific properties that were not 
utilized before in computer-based drug discovery. After successful completion, it is our 
expectation that a new anti-cancer drug candidate will be discovered, and a novel way of protein 
intrinsic disorder-based drug discovery will be verified. 
2.2 Results 
2.2.1 Myc & MBD2 intrinsic disorder similarity 
The Myc targeting drug, 10058-F4, has shown intriguing potential for targeting the 
intrinsically disordered regions with small drug-like molecules [52, 101, 102]. However, there 
was no computer-aided drug discovery trial to challenge the promising druggable intrinsically 
disordered region.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 Intrinsic disorder scores and molecular docking results for MBD2 and Myc. 
A-B: Similarity between the intrinsic disorder profiles of MBD2 (A) and Myc (B). Both panels 
have similar legends. Pink bar represents each protein’s partner binding site (p66α for MBD2, 
and Max for Myc). C-D: Molecular docking results for MDB2. C. ZINC40430779, D. 
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ZINC60177071 (Table 2.1). E: Molecular docking results for the Myc inhibitor (10058-F4), 
positioned at already known binding site (Y402) [100, 101]. 
 
Myc, and MBD2 have common structural characteristics where the disorder-to-order 
transition takes place when each of these two proteins binds to their partners, Max, and p66α, 
respectively [95, 99]. Both proteins have α-helical structure in their bound states, and 
distributions of the intrinsic disorder propensity within their sequences showed similar pattern in 
the region corresponding to the their binding site utilized for interaction with their partners 
(Figure 2.1A, B). For both proteins, there is a specific pattern in their disorder profiles, where the 
intrinsic disorder score increases while moving from the ordered N-terminal part to the 
disordered C-terminal part of an α-helix that is formed at interaction of these proteins with their 
partners. The biochemical similarities of those sites were further confirmed through the 
structural and sequence alignment (Table 2.1, Figure 2.2). 
 
 
 
 
 
 
 
Figure 2.2 Structural and sequence alignments of MBD2 and Myc. A. PDB 2L2L first 
frame (chain A; p66α, green / chain B; MBD2, blue), and PDB 1NKP (chain A; Myc, red / 
chain B; Max, yellow) structural alignment focusing on binding sites (MBD2 366-383, Myc 
402-412). B. Sequence alignment on coiled-coil part of above PDB files. C. Sequence 
alignment focusing on already known binding sites (MBD2 366-383, Myc 402-412). 
 
Table 2.1 Sequence Alignment Information 
Protein UniProt ID 
PDB 
(chain) 
PDB 
residues 
UniProt 
corresponding 
residues 
PDB 
binding 
residues 
UniProt 
binding 
residues 
MBD2 Q9UBB5 
2L2L 
(B) 
211-244 360-393 217-234 366-383 
Myc P01106 
1NKP 
(A) 
900-981 353-434 949-959 402-412 
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2.2.2 MBD2-p66α inhibitor discovery 
Applying molecular docking, we could find two compounds that were predicted to 
favorably bind to MBD2 (Table 2.2). Both compounds showed favorable binding energy scores 
(ZINC40430779: -35.2 kcal/mol, ZINC60177071: -33.3 kcal/mol). Also, there were three 
hydrogen bonds between each compound and MBD2 (Figure 2.1C, D, Table 2.2). 10058-F4 
showed a less favorable energy score (-6.77 kcal/mol), and there was just one hydrogen bond 
between 10058-F4 and Myc (Figure 2.1E). 
Table 2.2 Molecular docking result of MBD2-p66α inhibitor ligand discovery (H-bond; Hydrogen 
bond) 
 
 
2.2.3 Molecular Dynamics Simulation of the MBD2-Ligand Interactions 
Molecular docking experiments of two identified compounds were performed targeting 
the p66α binding-residues of MBD2 that were identified based on the previously determined 
MBD2-p66α structure (Table 2.1) [95]. Then, molecular docking results were used as starting 
points for the MD simulations. In the case of 10058-F4, Y402 was targeted for molecular 
# Structure ZINC ID 
Energy 
Score 
(kcal/mol) 
Number of 
H-bond 
H-bond 
Residues 
Net 
Charge 
(pH 7.0) 
MW 
(g/mol) 
(pH 7.0) 
1 
 
40430779 -35.2 3 
MBD2 
 
E373 : 2 
Q377 : 1 
1 223.252 
2 
 
60177071 -33.3 3 
MBD2 
 
E373 : 2 
Q377 : 1 
1 244.315 
3 
 
12406716 
(10058-F4) 
-6.77 1 
Myc 
 
Y402 : 1 
0 249.36 
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docking (Figure 2.1E) [100, 101]. Among the outputs of those MD simulations, I369com1/2 (I369 
of MBD2 targeted by the compounds 1 and 2) and the 10058-F4 and Myc results were analyzed 
in more detail. 
The time course of the contact number between the compound and protein showed 
relatively stable and constant patterns in the 50 ns trajectory describing the 10058-F4 – Myc 
complex (Figure 2.3A). On the other hand, the I369com1/2 50 ns trajectories were rather 
different. Contacts were present mainly within the 0~35 ns frame of the I369com1 trajectory. In 
the case of I369com2 trajectory, three contact periods were found, 0~5 ns, 10~15 ns, and 
47~50 ns. However, the average number of contacts per frame was greatest in the I369com1 
trajectory (Table 2.1, Figure 2.3B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3 Contact number analysis on three 50ns MD simulations; I369com1 (MBD2 
I369 targeted molecular docking result of compound 1(ZINC40430779) based MD simulation), 
I369com2 (MBD2 I369 targeted molecular docking result of compound 2(ZINC60177071) 
based MD simulation), and 10058-F4 (cMyc’s already known 10058-F4 binding site targeted 
molecular docking result based MD simulation). MBD2 residue numbers span 358-393, Myc 
residue numbers span 395-430. A Chronological contact number variations. B Average 
number of contacts. All of three averages were significantly different each other. C 
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Normalized contact number of each residue; each residue’s contact number was divided by 
total contact number. D368 is highlighted due to its density at the heatmap of I369com1 result. 
The residues followed MBD2 sequence of PDB 2L2L first frame chain B. 
 
From the contact numbers of these three trajectories corresponding protein-compound 
contact heat-maps were generated (Figure 2.3C). As it is shown in Figure 2.3C, MBD2 D368 
was the most contacted residue in the I369com1 trajectory, and the 10054-F4 – Myc trajectory 
showed L404 residue of Myc as the residue with the most number of contacts. Although Q223 
residue of MBD2 showed high contact density in the I369com2 trajectory, it was less contacted 
than the other two most contacted residues.  
Based on these results, we could define the bound status to be 0~20 ns for I369com1 
system, and 0~5 ns in the I369com2 system. To evaluate structural changes introduced by the 
binding of compounds 1 and 2 to MBD2, we compared the corresponding trajectories with the 
50 ns trajectories of apo MBD2 and the MBD2-p66α complex. MBD2 backbone RMSF showed 
that residual backbone fluctuations were not much different from each other at residues V376 
and L383, except in the trajectory obtained for apo MBD2 (Figure 2.4A). Among the three 
remaining trajectories (i.e., without considering the apo MBD2 trajectory), the backbone of the 
I369 residue within the MBD2-p66α trajectory showed more fluctuations than within the two 
other trajectories of bound compounds 1 and 2 (I369com1/2). However, D366 showed a 
different pattern. The backbone fluctuations of D366 within the I369com1 trajectory were 
intermediate between those detected in MBD2-p66α and I369com2 trajectories. Greater 
fluctuations were found for the MBD2-p66α complex trajectory, and smaller fluctuations were 
seen in the I369com2 results. To further investigate the structural changes, we measured Φ, Ψ 
angles of MBD2 binding residues (MBD2 D366, I369, V376, and L383) [95] (Figure 2.4B-E). 
Through two tailed T-tests (Table 2.3, 2.4), it was verified that compound 1 / 2 cause structural 
changes in the bound states. Both of compounds’ bound states showed significantly different Φ, 
Ψ angles from MBD2, and MBD2-p66α except three cases among 32 comparisons. 
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Figure 2.4 RMSF & Ramachandran plots A Backbone root-mean squared fluctuations 
(RMSF), and B-E Ramachandran plots of binding residues at four MD simulation results; 
MBD2 (MBD2 apo), MBD2-p66α (MBD2-p66α apo), I369com1(20ns) (I369com1 in bound 
status), I369com2(5ns) (I369com2 in bound status). A RMSF plot; four binding residues 
(D366, I369, V376, L383) were marked with different shapes on line. B-E Ramachandran 
plots of four binding residues (D366, I369, V376, L383, respectively, C-E legends are same 
with panel B). Corresponding Φ, Ψ angles’ 95% CI are listed in Table 2.3, and, corresponding 
two-tailed T-test p-values are listed in Table 2.4. 
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Compound bound states I369 Φ angle was not significantly different from MBD2-p66α. 
Also, the L383 Φ angle of compound 2 bound state in the I369com2 trajectory was not 
distinguished from the MBD2 apo trajectory. I369 played a role as structural torsion turning 
pointin in the I369com1, and I369com2 bound states. The N terminal part of I369 (D366 Φ, Ψ, 
and I369 Φ) showed no meaningful differences. However, remaining C terminal p66α binding 
residue angles showed significant differences. 
 
Table 2.3. 95% Confidence interval (CIs) of Φ and Ψ angles during the analysis of the bound states 
(0-20 ns for I369com1, and 0-5 ns for I369com2) 
 
Residue MD simulation Φ Ψ 
D366 
I369com1 (-60.75, -59.91) (-37.22, -36.38) 
I369com2 (-61.49, -60.07) (-36.82, -35.50) 
MBD2 (-74.67, -73.43) (-23.32, -22.10) 
MBD2-p66α (-63.59, -63.14) (-32.15, -31.68) 
I369 
I369com1 (-63.36, -62.76) (-42.61, -42.04) 
I369com2 (-63.53, -62.40) (-43.59, -42.48) 
MBD2 (-64.72, -64.25) (-41.26, -40.80) 
MBD2- p66α (-63.27, -62.93) (-44.61, -44.30) 
V376 
I369com1 (-61.77, -61.24) (-42.00, -41.44) 
I369com2 (-62.83, -61.64) (-41.02, -39.78) 
MBD2 (-75.15, -74.11) (-27.99, -26.80) 
MBD2- p66α (-59.71, -59.41) (-45.48, -45.19) 
L383 
I369com1 (-64.03, -63.40) (-40.61, -39.96) 
I369com2 (-63.36, -62.26) (-42.88, -41.75) 
MBD2 (-63.73, -63.35) (-41.66, -41.28) 
MBD2- p66α (-61.48, -61.16) (-44.45, -44.14) 
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Table 2.4. T-test p-values for the Φ and Ψ angles during the analysis of the bound states (0-20 ns 
for I369com1, and 0-5 ns for I369com2) 
Residue 
Φ 
T-test 
I369com2  MBD2 
MBD2- 
p66α 
Ψ 
T-test 
I369com2 MBD2 
MBD2- 
p66α 
D366 
I369 
com1 
0.2856 <2.2e-16 <2.2e-16 
I369 
com1 
0.1096 <2.2e-16 <2.2e-16 
I369 
com2 
- <2.2e-16 
2.692e-
11 
I369 
com2 
- <2.2e-16 <2.2e-16 
MBD2 - - <2.2e-16 MBD2 - - <2.2e-16 
I369 
I369 
com1 
0.782 2.592e-13 0.8193 
I369 
com1 
0.0252 2.935e-12 < 2.2e-16 
I369 
com2 
- 1.458e-06 0.6651 
I369 
com2 
- 1.017e-10 
1.534e-
06 
MBD2 - - <2.2e-16 MBD2 - - < 2.2e-16 
V376 
I369 
com1 
0.02737 <2.2e-16 <2.2e-16 
I369co
m1 
1.392e-4 <2.2e-16 <2.2e-16 
I369 
com2 
- <2.2e-16 <2.2e-16 
I369co
m2 
- <2.2e-16 <2.2e-16 
MBD2 - - <2.2e-16 MBD2 - - <2.2e-16 
L383 
I369 
com1 
0.005058 0.3659 <2.2e-16 
I369 
com1 
1.773e-09 1.044e-09 <2.2e-16 
I369 
com2 
- 0.01336 <2.2e-16 
I369 
com2 
 0.005753 
9.003e-
11 
MBD2 - - <2.2e-16 MBD2   <2.2e-16 
 
2.2.4 MBD2-Ligand and p66α-Ligand Contact Pattern Analysis  
Since ZINC60177071 (Compound 2) showed profound p66α inhibition capability during 
the wet lab experiments (see Section 2.2.5), additional MD simulations of the p66α-ligand 
complexes were performed. Based on the results of these MD simulations, contact heat-maps 
were generated to see if there were different contact patterns in comparison with those found 
during the MD simulations of the MBD2-ligand complexes (Figure 2.5).  
Among the eight MBD2-ligand MD simulation sets (D366com1, I369com1, V376com1, 
L383com1, D366com2, I369com2, V376com2, L383com2), two compounds showed different 
binding patterns. ZINC40430779 preferentially bound at D368 in two sets: I369com1 and 
V376com1 (Figure 2.5A). Other MD simulation sets of the MBD2-ZINC40430779 complex did 
not show high residue specific binding. ZINC60177071 did not show residue specific binding 
within the MD simulation sets of the MBD2-ligand complex (Figure 2.5B). 
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 MD simulation sets of the p66α-ligand complexes (I145com1, L152com1, L159com1, 
R166com1, I145com2, L152com2, L159com2, R166com2) indicated E155 as a specific binding 
site except in the I145com2 and R166com2 trajectories. In fact, the I145com2 set showed 
specific binding at different residue (E151), whereas the R166com2 trajectory did not show any 
meaningful residue specific binding. 
Figure 2.5 Contact patterns of MBD2-ligand and p66α-ligand MD simulations. Red, and 
blue residues are binding residues, thus, those were targeted during molecular docking. 
MBD2 residue numbers span 358-393, p66α residue numbers span 136-178. A MBD2 & 
ZINC40430779 complexes B MBD2 & ZINC60177071 complexes C p66α & ZINC40430779 
complexes D p66α & ZINC60177071 complexes. 
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2.2.5 ZINC40430779 binds p66α, and ZINC60177071 binds MBD2   
 Co-immunoprecipitation (Co-IP) assays were used to analyze whether the two screened 
compounds can actually suppress the interaction between MBD2 and p66α (Figure 2.6B & C). 
3xFB- and Myc-labeled MBD2 and p66α protein overexpression vectors were transiently 
transfected into the 293T cell line. The resulting cell extracts were treated with each compound, 
followed by Co-IP assay. Both candidate compounds were confirmed to suppress the interaction 
between MBD2 and p66α in a compound concentration-dependent manner. 
Previous research reported that the expression of a target gene by the CBP transcription 
factor complex is suppressed by the intact NuRD Chromatin Remodeling Complex (CRC) or by 
the overexpression of the MBD2 or p66α proteins. In contrast, knocking-down of MBD2 or p66α 
induced target gene expression in undifferentiated MEL cells by suppressing the interaction 
between MBD2 and p66α (Kim et al., unpublished data). Therefore, Luc reporter assay was 
employed to analyze whether the reduced expression of the target gene of the CBP 
transcription factor complex by the overexpression of MBD2 or p66α is recovered by treatment 
with the screened MBD2-p66α interaction suppressors (Figure 2.6 D-E).  
The GATA1 enhancer region was transfected as a CP2c transcription factor target 
sequence to control the expression of the Luc reporter gene along with various combinations of 
CBP complex protein overexpression vectors into 293T cells. Interestingly, ZINC40430779 
(#086567, Fluorochem) recovered the suppressed expression of the target gene by the p66α 
overexpression, but failed to recover the suppression of the expression of the target gene by the 
MBD2 overexpression. The effects of ZINC60177071 (#080579, Fluorochem) were opposite to 
those of ZINC40430779. Therefore, it was inferred that ZINC40430779 binds to p66α to 
suppress the interaction with MBD2, while ZINC60177071 binds to MBD2 to suppress the 
interaction with p66α. 
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Figure 2.6 Inhibition evaluation. A Renamed compounds: #086567 for ZINC40430779, 
#080579 for ZINC 60177071. B-C Co-IP experiment results, which show MDB2-p66α 
inhibition. D-E Luc reporter assay results, which show p66α-ZINC40430779 binding and 
MBD2-ZINC60177071 binding. 
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2.2.6 Anti-Leukemia Effectiveness of p66α Inhibitor (ZINC40430779) at in vitro 
experiments   
 ZINC40430779 have shown anti-leukemia effectiveness through in vitro experiments 
(Figure 2.7). Cancer cell lines of various origins were analyzed to test whether their cell growth 
or death are affected by the two selected compounds. 
Lymphoid leukemia cell lines (Raji, Molt4, IM9, Jurkat, CCRF-CEM, and Daudi), myeloid 
leukemia cell lines (KCL22, MEL, THP-1, HL60, HEL, U937, KG-1, and K562), and solid cancer 
cell lines (HCT116 colon cancer cell line, BEAS2B lung epithelial cell line, 293T kidney cancer 
cell line, Hep3B liver cancer cell line, MCF7 and MDA-MB-231 breast cancer cell line, MCF10A 
breast epithelial cell line, and U373MG brain cancer cell line) were treated with the two 
compounds alone or in combination at different concentrations (0, 1, 10, 100, 1,000, and 10,000 
μM), and cultured for 4 days. MTT assay was conducted at intervals of 24 hours to measure the 
cell viability. At 48 hours after treatment with the compounds, changes in the cell morphology 
were observed, and cell images were taken. IC50 values were also calculated for the treatment 
with each compound using the Graph Prism Pad 6 program. 
Fig. 2.7A shows all IC50 values obtained after each cell line was treated with the two 
compounds alone or in combination. Figure 2.7B-D show the cell viabilities of lymphoid 
leukemia cell lines (Daudi), myeloid leukemia cell line (MEL), and solid cancer cell line (Hep3B), 
and cell growth inhibition curves, IC50 values and representative cell images at 48 hours after 
treatment with the compounds. Taken together, ZINC60177071 did not affect cell growth in all 
cancer cell lines. Although the IC50 values of ZINC40430779 were considerably different in the 
cancer cell lines, ZINC40430779 showed low IC50 values (6-218 μM; average 50 μM) in the 
myeloid leukemia cell lines comparing to those  in the lymphoid leukemia and solid cancer cell 
lines (on average, 213 μM and 1776 μM, respectively). Therefore, ZINC40430779 is thought to 
be a leading substance for the development of the therapeutic agents for myeloid leukemia. 
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Figure 2.7 Anti-cancer effectiveness evaluation in diverse cancer cell lines. A Summary 
of IC50 values. B-D Cell proliferation assays, growth inhibition curves with IC50 values, and 
photographs of cells in several representative cancer samples, respectively. 
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2.2.7 Anti-Leukemia Effectiveness of p66α Inhibitor (ZINC40430779) at in vivo 
experiments 
Mice experiment confirmed the anti-leukemia therapeutic effect of ZINC40430779 
originally found in myeloid leukemia cell lines. Anti-leukemia effectiveness also occurred in 
myeloid leukemia cell line-transplanted animal models (Figure 2.8). Erythro-leukemias were 
formed in blood, spleen, and liver accompanying splenomegaly, when MEL cell lines were 
intravenously injected into immune-deficient mice in a previous study (Kim et al., unpublished 
data). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.8 Anti-cancer effectiveness evaluation in MEL cell injected mice models. A in 
vivo experiment design. B Mice, and tissue visual inspections. C Weight measurements of 
body, spleen, and liver. D Cell number measurements. E Tissue microscopy inspections. 
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Figure 2.9 Cell cycle arrest, and apoptosis induced by p66α Inhibitor (ZINC40430779).  
A-D Cell cycle analysis by FACS and western blots. E Western blots showing apoptosis-
related marker expression. 
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To test the cell death effects of ZINC40430779 in animal models, this compound was 
intravenously injected 5 times every 3 days from the day 7 after the first injection of the MEL 
cells (Figure 2.8A). On day 21, the mice were dissected, and analysis was conducted. 
Splenomegaly was suppressed by the ZINC40430779 administration in a concentration 
dependent manner, and no tumor cells were observed in blood, spleen, and liver. The overall 
hematological properties and the histological properties of the major organs were normal 
(Figure 2.8E). These results indicate that ZINC40430779 efficiently controls MEL cells without 
causing serious side effects in normal tissues/blood.  
 
 
2.2.8 p66α Inhibitor (ZINC40430779) disturbs cell cycle progression and induces 
apoptosis in myeloid leukemia cells. 
As an attempt to find the cause of the myeloid leukemia cell line-specific suppression of 
cell growth and tumorigenesis by ZINC40430779, the cell cycle changes caused by the 
compound treatment of the MEL cells were analyzed by FACS. A significant increase in the 
subG1 (dead cell group by apoptosis) phase was observed along with the decreased G0/G1 
phase and increased G2/M phase (Figure 2.9 A). In addition, an increase in the chromosome 
aneuploidy (cells with increased DNA amount caused by the suppressed cell division) was also 
observed (Figure 2.9 A). When the cells were synchronized to G1/S phase by thymidine double 
block and changes in cell cycle were measured by FACS after treatment with each compound, 
considerable chromosome aneuploidy was also detected. 
Changes in the cell cycle-related maker proteins expression were examined in cells 
treated with different concentration or treatment time of ZINC40430779 by western blot (Figure 
2.9 B-D). All of the cyclin/CDK complexes governing each cell cycle checkpoint were reduced 
by the treatment with ZINC40430779, suggesting that ZINC40430779 suppresses the overall 
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cell cycle progression, which is responsible for the induction of aneuploidy and cell death 
(Figure 2.9A). 
To determine whether the cell death induced by ZINC40430779 is caused by apoptosis, 
the expression levels of several apoptosis-related marker proteins were analyzed by western 
blot as time goes after treatment. The results showed that the expression of the anti-apoptotic 
markers was reduced while the expression of the pro-apoptotic markers was increased and the 
expression of the apoptosis-related caspases were activated (Figure 2.9E). In conclusion, since 
ZINC40430779 binds to p66α in the myeloid leukemia cell lines where MBD2 is expressed at 
low levels, it is suggested that the compound ZINC40430779 exhibits anticancer effects by 
efficient suppression of the permissive NuRD CRC function. 
 
2.2.9 Anti-Metastasis Effectiveness of p66α Inhibitor (ZINC40430779) & MBD2 
Inhibitor (ZINC60177071) 
Epithelial to mesenchymal transition (EMT) refers to a phenomenon in which epithelial 
cells are converted into mesenchymal cells. Cells having undergone EMT lose their cell-cell 
adhesion and acquire mobility, and as a result, they enter blood vessels and lymph nodes and 
migrate to organs to form metastatic cancer. Twist, Snail, Slug, Zeb1/2, etc. are known as major 
factors involved in the induction of EMT. It has recently been reported that Twist, which is 
known as a main regulator of EMT and cancer metastasis, interacts with the NuRD CRC and 
the reduced expression of the NuRD CRC constituent protein recovers the suppressed 
expression of E-cadherin, a target of Twist, and suppresses the occurrence of EMT [103].  
Thus, in an attempt to confirm whether EMT and cancer metastasis are suppressed by 
treatment with the two selected compounds, in vitro migration and invasion of cancer cells were 
analyzed (Figure 2.10). Two types of solid cancer cell lines (MDA-MB-231 breast cancer cell 
and HCT116 colon cancer cell line) and two types of leukemia (MEL murine erythroleukemia 
cell line and HL60 human promyelocytic myeloid leukemia cell line) were treated with 10 μM of 
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each compound using trans-well to analyze the migration and invasion of the cancer cells. The 
results revealed that the two compounds showed a significant inhibitory effect on the migration 
and invasion of all cell lines compared to the control, in which ZINC40430779 had an 
outstanding inhibitory effect on migration and invasion compared to ZINC60177071 (Figure 
2.10). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.10 Inhibitory effects of p66α Inhibitor (ZINC40430779) & MBD2 Inhibitor 
(ZINC60177071). A-B Migration inhibition. C-D Invasion inhibition. 
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2.3 Discussion 
Disorder-to-order transition sites, important for protein-protein interactions (i.e., sites that 
are disordered in the unbound state but can fold into more ordered structures at the binding site 
to specific partners) were identified from candidate factors satisfying the aforementioned 
requirements through bioinformatics techniques, including intrinsic disorder predictions.  
In our attempt to find candidate compounds, we have performed molecular docking and 
molecular dynamics simulations at sites where disorder-to-order transition is predicted to occur 
through protein interactions. We have also confirmed experimentally that the identified 
candidate compounds are effective cancer suppressants in the cellular and animal tumor 
models. 
The drug discovery mechanism developed and utilized in this study is based on a novel 
logistics. Although it has not been shown as of yet whether any of the two MBD2 inhibitors 
discovered in this study can cause structural changes in a target protein upon binding, previous 
studies involving the use of circular dichroism clearly showed that 10058-F4 binding to Myc 
induced a protein structural transition from a disordered to an α-helical structure [100]. It was 
also proposed that the inhibition mechanism of 10058-F4 is entropy driven [104]. In fact, IDP or 
IDPR are known to have high solvent accessible areas and therefore contain more surface 
located water molecules than ordered proteins and domains [105]. If a chemical compound with 
a high affinity to a certain disorder-to-order transition site within the IDPR approaches that site, 
the water molecules “bound” to that site are released, thereby increasing the entropy of the 
system satisfying the second law of thermodynamics. As a result, the foldable IDPR could 
become structured (e.g., could gain α-helical structure, as it was found in the Myc inhibition 
study, and as it probably happens in the case of MBD2 interaction with small molecules 
identified in this study), whereas the original binding partner of a target protein would lose the 
chance to promote a disorder-to-order transition. This mechanism could serve as a background 
logics for the drug discovery approach elaborated in this study. Although much additional work 
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needs to be done to verify the proposed mechanism, our study is supported by the previously 
discovered Myc inhibitors. 
Therefore, to the best of our knowledge, a drug discovery platform proposed in this study 
and specific anticancer candidates found using this platform are novel. This approach has 
promising outcomes and is expected to provide a novel break-through basic technology that can 
be efficiently used to discover novel cancer therapies. In addition, since disorder-to-order 
transitions are a common theme of the disorder-based interactions, and since these interactions 
are common feature of proteins related to the pathogenesis of various diseases, there is a high 
likelihood that this approach can also be used for identification of candidate compounds 
targeting different diseases, including novel anticancer drugs (e.g., novel inhibitors of cancer 
metastasis and new therapeutic agents for leukemia). 
2.4 Methods 
2.4.1 Analysis of Myc and MBD2 intrinsic disorder similarities 
To find similarities between Myc and MBD2, we conducted structural and sequence 
alignments using PyMOL 1.3, and Clustal O 1.2.1, embedded in UniProt [106-108]. 2L2L first 
frame chain B, and 1NKP chain A were chosen from Protein Data Bank as representatives of 
the MBD2 and Myc structures, respectively [69, 95, 99]. Because there were mismatched 
residue numbers between the PDB format and UniProt format, we selected corresponding 
regions from the UniProt based on the ‘DBREF’ entries of each PDB file (Table 2.1).  
To predict each intrinsic disorder patterns in query proteins, PONDR-FIT, VLXT, and 
VSL2 intrinsic disorder predictors were applied [57, 60, 62]. Then, for each protein, the average 
disorder score was calculated using the results of three individual predictors. 
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2.4.2 Molecular docking for MBD2-p66α inhibitor ligand discovery 
Because p66α L159 (PDB file 2L2L, first frame chain A) is known as binding partner of 
MBD2 [95], we used ‘startdockblaster5c’ algorithm embedded in DOCK 3.5.54 with ZINC 
database to search for ligand candidates targeting MBD2 (PDB file 2L2L first frame chain B) [70, 
75, 109]. Default parameters were used and only ‘vdW scale’ was adjusted from ‘1.0’ to ‘1.2’ 
during molecular docking. Among 1,000 found compounds, only two candidates were chosen, 
because they showed closest distance to the MBD2 binding residues and were characterized by 
the greatest negative energy and reasonable bound structures (Table 2.2).  
For MD simulation preparation, ‘startdockblaster4c’ algorithm of DOCK was used, and 
two compounds identified at the first stage were used as a library. Molecular docking 
environment was the same as at the previous ‘startdockblaster5c’-based step. Each of four of 
the already known MBD2 residues responsible for p66α binding was targeted [95]. To verify 
contact pattern of the p66α-ligand complex, the four p66α residues already known to be related 
to MBD2 binding were docked with two compounds. As a control in the MD simulation study, 
10058-F4-bound Myc was prepared in same way. Hydrogen at nitrogen of the five-member ring 
of 10058-F4 were edited using the Avogadro 1.1.1 algorithm followed by utilizing its energy 
minimization algorithm [110]. MBD2-aligned part of Myc (36 residues) was obtained from PDB 
file 1NKP chain A, and using in the molecular docking experiments as a target, according to 
previous study [101]. 
 
2.4.3 Molecular dynamics simulation, and Analysis 
To further evaluate the capabilities of the candidate compounds to serve as potential 
drugs, MD simulations were performed. Because ZINC40430779 showed promising 
effectiveness during several in vitro tests, this compound was chosen as an effective drug 
candidate. ZINC60177071 was chosen as a control due to its non-effectiveness in the wet lab 
experiments, even though it has similar chemical properties with ZINC40430779 (Table 2). 
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10058-F4 drug targeting Myc was chosen as another control due not only to its actual 
effectiveness, but also because of the fact that the Myc region targeted by this drug has intrinsic 
disorder pattern similar to that found in MBD2 region engaged in interaction with p66α. One 
should also keep in mind that the chemical properties 10058-F4 are different from those of two 
compounds targeting MBD2 [100, 101]. Parameters of those compounds were obtained using 
CGenFF 0.9.7.1 beta program, embedded within the ParamChem web interface [111, 112]. 
Only 10058-F4 parameters were adjusted using CHARMM 36 CGenFF force-field [113]. Finally, 
those CHARMM parameters were converted into Gromacs format using a python code 
‘cgenff_charmm2gromacs.py’ located at the MacKerell Lab homepage 
(http://mackerell.umaryland.edu/charmm_ff.shtml). 
The structures resulting from the molecular docking by ‘startdockblaster4c’, as well as 
structures of the unbound form of MBD2 (PDB ID 2L2L first frame chain B) and MBD2-p66α 
complex (PDB ID 2L2L first frame chain A & B) were prepared to enter MD simulations. 
According to in vitro biochemical MBD2-C60177071, and p66α-C40430779 binding evaluations, 
p66α structure (PDB file 2L2L first model chain B G136-K178) was prepared for additional 
molecular dynamics simulation preparation. From the structure, I145, L152, L159, R166 
coordinates were targeted for ‘startdockblaster4c’ application. The two chemical compounds 
were used as library. For all MD simulations, Gromacs 5.0.4 double precision version installed 
with FFTW 3.3.4 library, and the CHARMM 36 force-field, provided by the MacKerell Lab 
homepage were used [114-116]. Truncated octahedron box with periodic boundary condition 
was constructed with buffering area thickness of 1.2 nm. For explicit water models in MD 
simulation systems, ~14,200 TIP3P water molecules were constructed (16,116 TIP3P water 
molecules were used only in MBD2-p66α complex system) [117]. Then, ~100 mM of KCl ions 
were put to the system [118]. The number of ions was adjusted to neutralize the system, if 
necessary. Then, energy minimization using steepest descent method was performed until 
maximum force was less than 1000 kJ mol-1 nm-1, with initial step size of 0.01 nm. 
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During heating process, 2 ps (1000 steps with Δt = 2 fs) of each short NVT ensemble-
position restrained MD simulations were performed at three different temperatures, 100 K, 200 
K, and 310 K. At each NVT condition, velocities were generated according to the Maxwell 
distribution. Position restraint constant of 1000 kJ mol-1 nm-2 was applied to all heavy atoms, 
and V-rescale was used to control temperature [119]. The bond length with H-atoms were 
constrained using LINCS method [120]. For long-range electrostatics calculations, Particle mesh 
Ewald method (PME) was used [121, 122]. Verlet cut-off scheme was used to update neighbor 
list every 10 fs. Electrostatic cutoff, and van der Waals cutoff were set to be 1.2 nm. 
Equilibration process was performed with three continued 1 ns NPT ensemble-position 
restrained MD simulations with three different position restraint constants, 1000 kJ mol-1 nm-2, 
100 kJ mol-1 nm-2, and 10 kJ mol-1 nm-2. At each NPT condition, temperature was maintained to 
be 310K, and velocities were generated from previous step. Other parameters were maintained 
the same those utilized during the heating process, except for the pressure control. Parrinello-
Rahman barostat was applied with 4.5e-5 bar-1 isothermal compressibility of water to maintain 
the pressure of the system at 1 bar [123, 124]. 
During production runs, all 50 ns MD simulations were performed with NPT ensemble 
without position restraint. All the applied parameters were the same as those of the equilibration 
step, except for the position restraint condition. Every 10 ps, a frame was stored to prepare 
trajectories for further analyses. 
Backbone root-mean squared deviation (RMSD) was calculated using Gromacs 5.0.4 
‘rmsdist’ algorithm with reference structure of each result of energy minimization. Residue 
backbone root-mean squared deviation (RMSF) was measured using Gromacs 5.0.4 ‘rmsf’ 
algorithm. Contact numbers were calculated using Gromacs 5.0.4 ‘mindist’ tool. A contact 
between protein and compound was defined as a pair with the distance less than 3 Å  between 
any type of atoms of the protein and compound (Figure 2.3) [125]. However, in case of the 
MBD2-ligand and p66α-ligand contact pattern analysis (see Section 2.2.4), a pair of heavy 
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atoms with the distance less than 3.6 Å  between compound and protein in the corresponding  
trajectories was considered as a contact (Figure 2.5) [126]. After the contact measurements, all 
the numbers were normalized to the total contact number in a set. Interaction energy was 
calculated using ‘NAMDenergy’ plugin embedded in the VMD 1.9.1 platform [127, 128]. The 
values of Φ and Ψ angles were calculated using Gromacs 5.0.4 ‘rama’. R 3.1.2 was applied to 
calculate the T test p-values [129]. 
 
2.4.4 Cell culture 
The murine erythroleukemia (MEL), kidney cancer (293T), breast cancer (MDA-MB-231 
and MCF7), liver cancer (Hep3B), brain cancer (U373MG) cells were maintained in the 
Dulbecco’s modified Eagle’s medium (DMEM, Hyclone), whereas lymphoid leukemia (Raji, 
Molt4, IM9, Jurkat, CCRF-CEM, Daudi), myeloid leukemia (KCL22, THP-1, HL60, HEL, U937, 
KG-1, K562), and colon cancer (HCT116), lung epithelial (BEAS2B) cells were cultured in RPMI 
1640 (Hyclone) supplemented with 10% of fetal bovine serum (Hyclone) and 1% 
penicillin/streptomycin. The breast epithelial cell line (MCF10A) was maintained in DMEM/F12 
(Hyclone), supplemented with 5% Horse serum (Invitrogen), 500 ng/ml hydrocortisone (Sigma 
Aldrich), 100 ng/ml cholera toxin (Sigma Aldrich), 10 μg/ml insulin (Invitrogen) and 20 ng/ml 
epidermal growth factor (Sigma Aldrich), 1% penicillin/streptomycin. All cell lines were cultured 
in a 5% CO2 atmosphere. Chemical compounds, ZINC40430779 (#086567) and 
ZINC60177071 (#080579), were purchased from Fluorochem (UK) and made 1 M stocks in 
Phosphate buffered saline (PBS).  
 
2.4.5 Antibodies 
Antibody names and their sources used in this study are as follows: antibody against 
Flag (F1804) from Sigma Aldrich; antibodies against Cyclin A (ab38) and Cyclin B1 (ab72) from 
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Abcam; antibodies against Bcl2 (51-6511GR) and Bax (556467) from BD; antibodies against 
Snail (3879), pCDK1 (9114), and Cleaved Caspase3 (9661) from Cell Signaling; antibodies 
against β-catenin (sc7199), E-cadherin (sc8426), N-cadherin (sc7939), Slug (sc10436), Zeb1 
(sc10572), Twist (sc15393), p21 (sc6246), p53 (sc6243), CDK2 (sc163), Cyclin D (sc8396), 
Cyclin E (sc198), Chk1 (sc7898), CDC25c (sc13138), Mcl-1 (sc819), Bcl-xL (sc7195), Bim 
(sc11425), Casepase3 (sc7148), Caspase 8 (sc7890), Caspase 9 (sc7885), Caspase 11 
(sc15881), Caspase 12 (sc5629), and β-Actin (sc-1616) from Santa Cruz; antibodies against 
CDK1 (06-923) and CDK4 (06-139) from Upstate; antibody against Myc (G077) from Abm; 
antibody against Bak (AM03) from EMD. 
 
2.4.6 Co-immunoprecipitation 
293T cells were transfected with the equal amounts of plasmids encoding p66α and 
MBD2 (pEF1α-3X Flag p66α and pCMV Tag2B-Myc-MBD2). Cell lysates were prepared from 
cells 48h after transfection with a lysis buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM 
EDTA, 1% NP40, and 1 mM PMSF) and incubated in the presence of various concentration of 
ZINC40430779 or ZINC60177071 for 15 min. Pre-cleared lysate using protein A/G (Santa Cruz) 
was immunoprecipitated with either monoclonal anti-Flag or polyclonal anti-Myc antibody 
overnight at 4 °C. After addition of protein A/G beads to the reaction for additional 3 h, the bead-
bound Immunocomplexes were washed with lysis buffer three times and then eluted with 2X 
SDS loading buffer. Precipitated proteins were separated in 10% SDS-PAGE and subjected for 
western blot. 
 
2.4.7 Transfection and Luciferase Reporter Assay 
293T cells (1 x 105) in 12-well tissue culture plates were transiently transfected with a 
mouse GATA-1 enhancer-driven luciferase reporter construct (pGL3-TATA-GATA-1 enhancer), 
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along with the CP2c, CP2b, PIAS1, p66α, and MBD2 expression vectors in various 
combinations, using Effectene (QIAGEN). Cells were harvested 48 h after transfection in 100 μl 
passive lysis buffer (Promega), and then 20 μl of lysate was used for luciferase assays on a 
Lumat LB9501 luminometer (Berthold) using a dual-luciferase assay system (Promega). Firefly 
luciferase expression was normalized against Renilla luciferase and the data was represented 
as the ratio of firefly to Renilla luciferase activity (Fluc/Rluc). All experiments were repeated at 
least two times independently. 
 
2.4.8 In vitro migration and invasion analysis 
Cell migration and invasion assays were performed in the transwell chamber (8 μm, 24-
well insert; Corning, USA). For migration assays, cells (1×104) were seeded on the upper 
chamber in serum-free medium containing 10 μM ZINC40430779 or ZINC60177071; the lower 
chamber was filled with medium containing 10% FBS, and 10 uM ZINC40430779 or 
ZINC60177071. Cells were then incubated for 48 h. For invasion assays, cells were cultured 
under same conditions to the migration assay, except the insert chamber membrane was 
coated with the 1:10 diluted Matrigel (BD Biosciences). Cells migrated or invaded into the lower 
chambers were fixed with methanol, and then stained with Diff Quik Stain Kit (Sysmex 
Corporation, Japan). Cell numbers were scored in four random 40 x microscopic fields for 
statistical analyses. 
 
2.4.9 Western blot 
Cell extracts were prepared using the lysis buffer (50 mM Tris-HCl, pH 7.4, 150 mM 
NaCl, 1 mM EDTA, 1% NP40, and 1 mM PMSF). Aliquotes of the whole cell extract were 
electrophoresed on 10% SDS-PAGE gels and transferred to a PVDF membrane (GE 
healthcare). The membrane was blocked and incubated with appropriate dilutions of the primary 
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antibody at room temperature for 1 h. After washing, a 1:10000 dilution of the appropriate 
secondary antibody (horseradish peroxidase-conjugated) was added at room temperature for 1 
h. Polyclonal anti-β-actin antibody (Santa Cruz) was used as a loading control for 
immunoblotting. Proteins were visualized by chemiluminescence using an ECL system 
(Amersham-Pharmacia).  
 
2.4.10 Cell viability test 
Cell viability was assessed using MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) assay. Briefly, each fresh cells were seeded in flat-bottomed 96-
well tissue culture plates (Corning Inc., NY) at a concentration of 3,000 cells/well with complete 
culture medium and incubated for 1h. The cells were incubated in 50 μl culture medium 
containing 0 to 10 mM ZINC40430779 or ZINC60177071 for 24, 48, 72, or 96 h. MTT (5 mg/ml) 
solution was added and the cells were incubated for an additional 2h. MTT medium was 
discharged, and the formazan crystals were dissolved using 100 μl dimethyl sulfoxide (DMSO) 
per well. The formazan concentration was measured spectrophotometrically at 490 nm using a 
Multiskan EX (Thermo). IC50 values were determined from the nonlinear repression curves 
(Graphpad Prism). 
 
2.4.11 Animal study (Xenograft) 
For xenografts, 30 four-week-old BALB/c nude mice (Nara Biotec) were randomly 
divided into ten groups (3 mice per group). Approximately 100 μl PBS of single cell suspension 
(5 × 106 cells) of MEL cell lines were injected via tail vein. One day or one week after inoculation, 
mice were injected i.v. with ZINC40430779 (12.2, 24.4, or 48.8 μg/kg) or PBS, a total of 5 times, 
once every 3 d. The mice were sacrificed 3 days after the last injection. Blood samples were 
collected for complete blood cell counting analysis by the CBC automated analyzer. Major 
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tissues were immediately fixed in 10% formalin neutral buffer solution. H&E-stained sections 
were observed and photographed by the light microscopy, and the representative histological 
images were recorded at ×400 magnification. All animal procedures were approved by the 
Animal Care and Use Committee and the Institutional Review Board of Chung-Ang University. 
 
2.4.12 FACS 
MEL cells were seeded in 100 mm dishes and cultured with culture medium containing 
ZINC40430779 (16.5 μM). At indicated time points (0, 24, 48, or 72 h), cells were harvested and 
fixed in 70% ethanol at −20°C. Before analysis, cells were incubated with RNase A (20 μg/ml) at 
37°C for 30 min and stained with PI (50 μg/ml) at room temperature for 20 min. Samples were 
immediately analyzed by flow cytometry with a FACS Calibur flow cytometer (BD Biosciences). 
The cell fractions in sub-G1, G1, S, and G2/M phases were quantified in histograms with FlowJo 
software (BD Biosciences). 
 
2.4.13 Thymidine double block 
Cells were synchronized in the G1 phase with a double thymidine block. 5 × 105 cells 
were plated in 100 mm dishes, and thymidine was added to a final concentration of 2 mM. The 
cells were cultured for 12 h. After removal of the thymidine and incubation for 9 h in the fresh 
DMEM medium, thymidine was added to a final concentration of 2 mM for an additional 12 h. 
After removal of thymidine again, synchronized cells were cultured in fresh DMEM or DMEM 
containing 100 μM ZINC40430779 medium and collected at different times for cell cycle 
analysis. 
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2.4.14 Karyotyping 
MEL cells were cultured in the presence or absence of ZINC40430779 for 48 h and 
transferred to DMEM supplemented with 25 ng/ml colchicine. After 9 h of incubation, cells were 
then incubated with hypotonic solution (0.075 M KCl) at 37°C for 15 min. Thereafter the cells 
were treated with acetic acid and methanol (1:3) fixative solution 3 times. Finally, the prepared 
slides were heat fixed and stained with 5% Giemsa solution. For evaluating chromosomal 
aberration, chromosome numbers were scored under the inverted microscope BX50 (Olympus) 
at 1000 X magnification. 
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CHAPTER 3. MOLECULAR DYNAMICS (MD) SIMULATION ANALYSIS OF 5-
AMINOLEVULINATE SYNTHASE  
 
Note to reader 
 Part of this chapter was published in Na I, Deforte S, Stojanovski B, Ferreira G, Uversky 
V. 2017 Molecular dynamics analysis of structural and dynamic properties of the functionally 
enhanced hepta-variant of mouse 5-aminolevulinate synthase. Journal of Biomolecular 
Structure and Dynamics. 9:1-14 DOI: 10.1080/07391102.2016.1269688, and have been 
reproduced under copyright permission by Copyright Clearance Center (Appendix A, C). 
3.1 Introduction 
3.1.1 5-Aminolevulinate Synthase (ALAS), and X-linked Protoporphyria (XLPP) 
Heme serves as a prosthetic group for a number of proteins involved in the transport and 
storage of divalent gases, redox reactions, electron transport and regulation of biological 
processes as distinct as transcription, translation, microRNA processing, cell cycle and 
neutrophilic activation [130]. In metazoa and certain bacteria, the initial, and regulated, step of 
heme biosynthesis is catalyzed by the pyridoxal  5’-phosphate (PLP)-dependent enzyme 5-
aminolevulinate synthase (ALAS), in a reaction during which 5-aminolevulinate (ALA) is 
generated upon the condensation of glycine and succinyl-CoA [131, 132]. Subtle disturbances 
in the rate of ALA formation as a consequence of gain-of-function and loss-of-function mutations 
in the erythroid-specific ALAS gene (ALAS2) result in the erythropoietic disorders X-linked 
protoporphyria (XLPP) and X-linked sideroblastic anemia (XLSA), respectively [133, 134].   
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3.1.2 5-Aminolevulinate Synthase (ALAS) and Structural Studies 
Detection of a pre-steady-state burst of ALA formation under saturating conditions of 
substrates clearly demonstrated that the rate of the ALAS-catalyzed reaction is limited by the 
release of ALA from the active site of this enzyme, rather than by ALA formation [135]. Based 
on the experimental evidence for accumulation of the product ALA at the enzymatic active site, 
the slowest step of the reaction rate can be explained by two likely scenarios, which are not 
completely mutually exclusive. In the first scenario, the rate-limiting step of the reaction is 
dominated by the transaldimination reaction during which the covalent linkage in the ALA-
external aldimine intermediate (ALA-PLP complex) is labilized, and an internal aldimine adduct 
between PLP and the catalytic lysine [Lys 313 in murine ALAS2 (mALAS2)] is formed. In the 
second scenario, the pre-steady-state accumulation of ALA at the active site results from a slow 
conformational transition of the enzyme, which necessitates the opening of the active site via 
gaining a conformation that can favor the release of ALA.  
With the elucidation of the crystal structure of Rhodobacter capsulatus ALAS [136], it 
became apparent that the enzyme, even in the absence of substrates, populates at least two 
distinct conformations. These two conformations, designated as open and closed, 
predominantly differ in the segmental rearrangements of a C-terminal loop and an α-helix that 
regulate the accessibility of the active site of ALAS [136]. Specifically, in the open conformation, 
the active site is more accessible for the entry of substrates and release of products (particularly 
ALA), while when populating the closed conformation, steric hindrances as a result of the 
closure of the active site loop and α-helix seem to disfavor the dissociation of ALA from the 
active site. Based on the crystallographic and kinetic analyses that had emerged thus far, 
Hunter et al. [137] postulated that the release of ALA from the active site is indeed dominated by 
the conformational transitions of the enzyme from the closed to the open conformation.  
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3.1.3 Functionally Enhanced Hepta-Variant of Murine ALAS Discovery 
In an attempt to validate these predictions, Lendrihas et al. [138] implemented 
saturations mutagenesis by targeting non-conserved amino acids at various positions of the 
flexible loop of mALAS2 that regulates the active site access in the analogous R. capsulatus 
enzyme. These researchers identified several hyperactive enzyme variants with steady-state 
kinetic parameters and specificity constants that were drastically increased over those of wild-
type mALAS2 [138]. Of particular interest was the impressive catalytic prowess of a hepta-
variant with kcat and kcat/KmSCoA values increased ~ 15- and 55-fold over those of the wild-type 
enzyme, respectively [138]. Importantly, the three kinetic steps that describe the kinetic trace for 
the reaction between the wild-type mALAS2-glycine complex and succinyl-CoA under single 
turnover conditions were no longer discernable in the reaction catalyzed by the hepta-variant, 
with the reaction being best described as a biphasic process [138]. The disappearance of the 
third kinetic step and the increased rate of catalytic turnover were postulated to originate from 
destabilization of the closed conformation as a consequence of the introduced mutations in the 
active site loop of the hepta-variant, which, in turn, led to the accelerated reversion to the open 
conformation and faster release of ALA from the active site [138]. 
 
3.1.4 Research Purpose, and Approach 
The aim of this research was to investigate, using molecular dynamics (MD) simulations, 
whether the seven simultaneous mutations in the mALAS2 dimer (hepta-variant) can induce 
structural changes with repercussions in the dynamic properties of the enzyme. Our main 
hypothesis is that the hepta-variant undergoes an early structural change in the mutated active 
site loop (UniProt ID P08680 residues Y500-R517 = mature mALAS2 residues Y422-R439), 
which affects the stability of the closed conformation of a protein and the return to the open 
conformation. We further hypothesize that this transition, from the closed to the open 
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conformation, occurs more rapidly in the hepta-variant than wild type enzyme – especially in the 
active site loop. 
3.2 Results 
3.2.1 Homology between Bacterial ALAS and Murine ALAS 
Sequence alignment between HemA and the mature form of mALAS2 showed 39% 
identity. Based on the sequence identity, we used the mALAS2 F143 – A587 sequence, which 
does not include the N-terminal tail (red box in Figure 3.1A), to prepare the mALAS2 homology 
model for MD simulations. However, we included the N-terminal helix (mALAS2 F143-H160 vs. 
HemA M1-G18; Figure 3.1B) in our mALAS2 homology model. The sequence corresponding to 
the active site loop (HemA Y357-E371, mALAS2 Y500-E514), which covers the previously 
identified seven mutation-stretch in an hyperactive mALAS2 variant [138], is denoted by a red 
arrow and labeled in red, while the contiguous β13 strand (HemA R372-F375, mALAS2 L515-
L518) is denoted by a blue arrow and labeled in blue in Figure 1A. The β13 strand was originally 
identified in the crystallographic structure of R. capsulatus HemA, chain D (PDB 2BWN) [136]. 
Upon homology modeling, the mALAS2 C-terminal tail (highlighted in blue shading in Figure 1A) 
rendered a tangled C-terminal tail structure (blue, Figure 3.1B). 
 
3.2.2 Intrinsic Disorder Changes in the Hepta-Variant forms of mALAS and HemA 
The seven mutations in the active site loop of the previously identified hyperactive, 
hepta-variant of mALAS2 were V501L, Y506R, P510E, R511I, G512N, E513Q and L515K 
(amino acid numbering according to UniProt ID P08680 for full-length mALAS2) [138]. To 
investigate the possible effect of these mutations in the dynamic properties of ALAS, initially we 
evaluated the distribution of intrinsic disorder propensities of the murine and R. capsulatus 
enzymes, mALAS2 and HemA, respectively, using the PONDR®  VLXT predictor [139, 140].  
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PONDR®  VLXT indicated an obvious difference in the mutated active site loop (HemA Y357-
E371, ALAS2 Y500-E514). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 Peculiarities of sequence and structure of mALAS2. A. Sequence alignment 
of the R. capsulatus HemA (or R. capsulatus_ALAS) and the mature form of mALAS2 (M. 
musculus_matureALAS2). The CLUSTAL O sequence alignment yielded ~ 40% identity, 200 
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identical and 128 similar amino acids, respectively, between the two proteins. The mALAS2 
sequence shaded in red was not included in the homology modeling of mALAS2. The 
mALAS2 sequence (F143-A587) was modeled, and the sequence shaded in green was the 
subject of our analysis in this study. The mALAS2 sequence shaded in blue corresponds to 
the C-terminal tail, which is absent in R. capsulatus HemA. The active site loop and the β13 
strand are labeled and denoted with arrows in red and blue, respectively. B. ALAS2 
homology model constructed using the ALAS2 sequence without the N-terminal helix, 
indicated in plot A., and the chain D coordinates from the PDB entry 2BWN (R. capsulatus 
HemA) as a homology template for the monomer. After the homology models of the 
monomers were constructed, two modeled monomers were structurally aligned with the 
chains D and E of the PDB entry 2BWN to generate the structure of mALAS2 dimer that 
contains chain A (green) and chain B (cyan). 
 
The local intrinsic disorder score increased from 0.2 (HemA-WT) to 0.6 (HemA-MT) in 
HemA sequences due to the seven mutations, i.e., hepta-variation (see Figure 2A). However, 
the same loop amino acid variations in mALAS2 had the opposite effect, with a decrease in the 
local intrinsic disorder score from 0.9 in wild type mALAS2 (ALAS-WT) to 0.8 in the hepta-
variant (ALAS-MT) (Figure 2B). PONDR®  VLXT is a first generation intrinsic disorder predictor 
that is able to identify function-related features in query proteins [139, 140]. 
Even though this is not the most accurate currently available predictor, it is characterized 
by a high sensitivity to local sequence peculiarities and can be used to identify disorder-based 
interaction sites [57] and evaluate potential consequences of point mutations on the local 
disorder propensities. Figure 2B shows that, in agreement with the available experimental data, 
the mutation-affected loop in the hepta-variant of mALAS2 is characterized by a decreased 
intrinsic disorder propensity. On the other hand, similar mutations introduced in the 
corresponding HemA active site loop resulted in the noticeable increase in local disorder 
propensity (Figure 2A). This finding was unexpected; however, it should be noted that no 
experimental evidence is presently available for the bacterial enzyme. 
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Figure 3.2 Effect of the seven mutations to the active site loop (hepta-mutation) on the 
intrinsic disorder propensities of R. capsulatus HemA and the mature form of mALAS2. 
A. The hepta-mutation caused a significant increase in the local intrinsic disorder propensity 
of the active site loop of HemA as indicated by red arrow. B. In mALAS2, hepta-mutation 
caused noticeable decrease in the intrinsic disorder propensity at the affected loop as shown 
by blue arrow. HemA-WT, wild type R.capsulatus HemA; HemA-MT, hepta-variant of 
R.capsulatus HemA; ALAS-WT, wild type mALAS2; ALAS-MT, hepta-variant of mALAS2. 
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3.2.3 Structural Changes during MD Simulation 
The 200 ns trajectories obtained during the production run were used to measure the 
backbone RMSD values every 100 ps (Figure 3.3). The reference frame of the RMSD 
calculations was the energy-minimized structure of each corresponding trajectory. Within the 
trajectories, the RMSD showed different patterns between the mALAS2 and HemA systems. In 
mALAS2 trajectories, the RMSD values for wild type and hepta-variant diverged twice, at ~60 ns 
and ~120 ns, regardless of the presence of absence of the N-terminal helix (Figure 3.3A and 
Figure 3.1). Similarly, the RMSD trends for the HemA systems containing the N-terminal helix 
were not significantly different from those for the HemA systems without the N-terminal helix 
(Figure 3.3A).   
While the time courses of the RMSD values determined for wild type mALAS2 and its 
hepta-variant, both containing the N- and C-termini, showed different patterns, there were no 
meaningful differences in their RMSD trajectories (Figures 3.3B and C). In the dimeric 
trajectories, all the monomers without N-helix and C-tails maintained the RMSD value of 2Å . 
However, the trajectory for chain A of the mALAS2 hepta-variant (ALAS-MTchA) with N-helix 
and C-tails differed substantially from that of its wild type counterpart. In fact, and in contrast to 
the RMSD trajectories for ALAS-WTchA and ALAS-WTchA without N-helix and C-tail, with 
differences not exceeding 2Å , the RMSD trajectories for the ALAS-MTchA devoid of the N- and 
C-termini were clearly distinct from those of the same mutated polypeptide chain but without the 
N- and C-termini (Figure 3.3B). 
RMSF analysis revealed differences in the two sets of ALAS systems (Figure 3.4). In the 
case of the HemA systems, the introduced seven mutations resulted in greater RMSF values in 
the active site loop of HemA-MT than those associated with the HemA-WT loop. This result 
corroborates the PONDR-VLXT intrinsic disorder prediction (Figure 3.2A). With the mALAS2 
systems, the RMSF analyses yielded dissimilar results depending on the polypeptide chain. 
Whereas a smaller RMSF value was associated with the active site loop in the mALAS2 
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polypeptide chain B (ALAS-MTchB) than with that in the corresponding wild-type polypeptide 
chain (ALAS-WTchB), the greater RMSF values were calculated for the ALAS-MTchA active 
site loop than that for the ALAS-WTchA loop (Figure 3.4B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3 Time-courses of the protein backbone dynamics evaluated by root-mean 
squared deviations (RMSDs) during the production runs. A. The RMSD trajectories for 
the wild type R.capsulatus HemA (HemA-WT) and hepta-variant of R.capsulatus HemA 
(HemA-MT) show divergence at ~60 ns, and ~120 ns. RMSD values for the HemA-WT 
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constructs (with and without N-terminal helix) were stabilized at the level of ~2 Å , whereas the 
RMSD values for HemA-MT were stabilized at the level of ~3 Å . B. The RMSD trajectories for 
the chain A of both wild type and mutant forms of mALAS (ALAS-WTchA and ALAS-MTchA, 
respectively) were different for the constructs containing the N-terminal helix and the C-
terminal tail. In the absence of the N-terminal helix and the C-terminal tail, ALAS-WTchA and 
ALAS-MTchA diverged at early stages of MD analysis, but then converged at later stages 
(after ~140 ns). Inclusion of the N-terminal helix and the C-terminal tail caused the ~1 Å  
RMSD increase for the ALAS-WTchA, but resulted in the ~4 Å  increase in RMSD for the 
ALAS-MTchA. C. RMSD trajectories for the chain B of both wild type and mutant forms of 
mALAS (ALAS-WTchB and ALAS-MTchB, respectively) with and without the N-terminal helix 
and the C-terminal tail were different from the RMSD trajectories of the corresponding ALAS-
WTchA and ALAS-MTchA constructs. In fact, introduction of hepta-mutation caused 
noticeable decrease in the backbone mobility of this chain both with and without the N-
terminal helix and the C-terminal tail. Plots B and C also show that the trajectories describing 
the backbone dynamics of the energy minimized structures of both mALAS2 monomers 
without the N-terminal helix and the C-terminal tail were eventually stabilized at the RMSD 
levels of ~2 Å . 
 
Thus, the RMSF analysis of the ALAS-MTchB, but not of the ALAS-MTchA, agrees with 
the PONDR-VLXT-predicted intrinsic disorder results (Figure 3.4B). Furthermore, we obtained 
per-residue average RMSF values for the two chains of ALAS-WT and ALAS-MT in both of the 
mALAS2 and HemA sets. Not only the mutated mALAS2 active site loop but also other regions 
of the protein showed lower RMSF values than those of wild type mALAS2. Likewise, the 
profiles of the per-residue RMSF values averaged over both chains of ALAS-MT were 
consistent with the PONDR-VLXT results for the active site loop (Figure 3.4C). The situation 
was reversed with HemA, with the hepta variant yielding greater RMSF values that the wild-type 
enzyme. Overall, the RMSD and RMSF analyses suggested that the seven simultaneous active 
site loop mutations cause mALAS and HemA to adopt distinct conformations. 
To visualize structural changes taking place during the MD simulations, we analyzed 
some of the structures along the trajectories. In agreement with the intrinsic disorder and RMSF 
analysis, we were able to detect structural changes within the mutated active site loop. At some 
points during the trajectories, mALAS-MT distinctively showed a new β-strand in the mutated 
active site loop. Therefore, we were motivated to measure the number of hydrogen bonds in the 
loop. 
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Figure 3.4 Analysis of the per-residue root-mean squared fluctuations (RMSFs) of the 
proteins during the MD simulations. A. Hepta-variations caused HemA-WT to be more 
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flexible than HemA-WT, especially within the affected loop. B. In the mALAS2, hepta-
variations caused each chain of the protein to be more stable than the corresponding chain of 
the ALAS-WT. However, ALAS-MTchA showed greater RMSFs than the ALAS-MTchB at the 
affected loop. C. The per-residue RMSF profiles averaged over the chains A and B of the 
ALAS-WT (blue line) and ALAS-MT (red line) show decreased RMSF of the affected loop for 
the mutated protein. Insets represent illustrative structures of the C-terminal region containing 
the active site loop, a new strand β13, and a β11-α13-β12 structural motif for the 
corresponding proteins. 
 
3.2.4 Hydrogen Bond Number Differences 
Because our structural observations (supported in part by intrinsic disorder and RMSF 
analyses) unveiled the emergence of a new β-strand in the mutated active site loop during the 
MD simulations using various forms of ALAS (i.e., mALAS2, R. capsulatus HemA, and hepta-
variants of mALAS 2 and HemA), we set to measure the number of hydrogen bonds formed 
between the active site loop (HemA Y357-E371 or mALAS2 Y500-E514) and β13 (HemA R372-
F375 or mALAS2 L515-L518), every 100 ps, to assess possible structural changes. In the initial 
HemA structure, the active site loop (i.e., the query region) did not contain a β-strand as 
described in [136]. In the HemA systems, the number of hydrogen bonds diverged at ~100 ns, 
with an increased number after this time point. During each of 200 ns trajectories, ~4 and ~3 
hydrogen bonds were formed in HemA-WT and HemA-MT, respectively (Figures 3.5A and B). 
While the number of hydrogen bond was smaller in the ALAS2 than HemA systems (Figures 
3.5A and B vs. 3.5C and D), ALAS-MTchA, from the starting point of the production step, 
maintained the highest number of hydrogen bonds among the mALAS2 system members. 
During the 200 ns trajectories, ALAS-WTchA, -MTchA, -WTchB, and -MTchB showed ~2, ~3, ~2, 
and ~1 hydrogen bonds, respectively (Figures 3.5C and D). 
The analysis of the ALAS2 monomeric structures, generated upon 100 ns, 150 ns, and 
200 ns MD simulations, allowed us to identify a β-strand within the former active site loop of 
ALAS-MTchA. By 200 ns, the β-strand had collapsed in the active site loop of ALAS-MTchA 
(Figure 3.5E). The progression of this secondary structure element, from β-strand to loop, is 
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likely associated with the more open conformation adopted by the active site loop in ALAS-
MTchA than ALAS-WTchA (Figure 3.5E ALAS-MTchA vs. ALAS-WTchA at 200 ns). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5 Number of hydrogen bonds between the active site loop (residues Y357-
E371 in HemA and residues Y500-E514 in mALAS2) and the β13 strand (residues R372-
F375 and L515-L518 in HemA and mALAS2, respectively) (Continued on Next Page).  
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Figure 3.5 Number of hydrogen bonds between the active site loop (residues Y357-
E371 in HemA and residues Y500-E514 in mALAS2) and the β13 strand (residues R372-
F375 and L515-L518 in HemA and mALAS2, respectively). A and B. For the HemA-WT 
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and HemA-MT pair, the greater number of hydrogen bonds was observed within the HemA-
WT trajectory (4.1 ± 0.5) than within the HemA-MT trajectory (3.0 ± 0.9). C and D. Among the 
mALAS2 chains, ALAS-MTchA showed the greatest number of hydrogen bonds, 2.6 ± 0.75, 
whereas ALAS-WTchA, ALAS-WTchB, and ALAS-MTchB were characterized by noticeably 
lower numbers of the hydrogen bonds, 1.7 ± 0.6, 1.3 ± 1.2, and 0.61 ± 0.62, respectively. E. 
and F. To visualize the dynamics of the C-terminal regions containing active site loop, strand 
β13, and β11-α13-β12 structural motif, sample dimer structures of the ALAS-WTChA and 
ALAS-MTChA (plot E) and the ALAS-WTChB and ALAS-MTChB (plot F)  were selected at 
100 ns, 150 ns, and 200 ns. Structures of the query C-terminal regions are shown in cyan, 
green, pink, and purple for the ALAS-WTchA, ALAS-WTchB, ALAS-MTchA, and ALAS-
MTchB, respectively. ALAS-MTchA clearly showed the presence of the β-strand within the 
affected loop. 
 
In addition, these structural and dynamic changes concur with the faster release of ALA 
from the active site of the hepta-variant than that of wild-type mALAS2, previously proposed to 
result from an accelerated reversion to the open conformation [138, 141]. Although no new β-
strand within the active site loop was present in the ALAS-WTchB and ALAS-MTchB structures, 
ALAS-WTchB was characterized by greater number of instances of formed hydrogen bonds 
inside the loop as it was shown in previous analyses (Figure 3.5C and D). 
 
3.2.5 Closed Conformation Determining Region Differences 
To verify whether the different conformations during MD simulation have relation to the 
open and closed states described upon analysis of the crystallographic structures of the HemA 
holoenzyme and HemA-succinyl-CoA complex [136] and deduced from the transient kinetic 
studies with mALAS2 [137, 138, 141, 142], the distance between the active site loop and a 
conserved methionine (HemA M190 or ALAS2 M333) was measured every 100 ps. In the 
closed conformation, HemA T365, positioned at the apex of active site loop, is stabilized by a 
hydrogen bond to R21 and van der Waals interactions with active site loop I361 and M190 [136]. 
These interactions serve as closed conformation determinants. After ~90 ns, the minimum 
distance between the loop and M190 in the wild type enzyme (HemA-WT) obviously diverged 
from that in the hepta-variant (Figure 3.6A). However, the difference between the averaged 
minimum distances for the HemA-WT and HemA-MT systems was not sufficient to cause the 
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observed structural divergence (0.9Å ). Specifically, the averaged minimum distances during the 
MD simulation were 2.2 Å , and 3.1 Å  for HemA-WT and HemA-MT, respectively (Figures 3.6A 
and 6B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6 Distance between the conserved methionine (M190 in HemA or M333 in 
mALAS2) and the loop affected by hepta-mutation (residues Y357-E371 and Y500-E514 
in HemA and ALAS2, respectively) (Continued on Next Page). 
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Figure 3.6 Distance between the conserved methionine (M190 in HemA or M333 in 
mALAS2) and the loop affected by hepta-mutation (residues Y357-E371 and Y500-E514 
in HemA and ALAS2, respectively). Plots A and B represent data for the HemA, whereas 
the results of the mALAS2 analysis are shown in plots C and D. The HemA-WT and HemA-
MT trajectories diverged starting from ~90 ns (plot A). The averaged minimal distances 
between their affected loop and conserved methionine were 2.2 ± 0.2 Å  and 3.1 ± 1.1Å  for 
HemA-WT and HemA-MT, respectively (plot B). The ALAS2 trajectories revealed that the 
ALAS-MTchA structure was characterized by the largest distances between the affected loop 
and conserved methionine (plot C), with the averaged minimal distance being 3.1 ± 1.5 Å  
(plot D), which was comparable with distances measured for the HemA-MT. Other mALAS2 
monomers showed the distances of 2.5 ± 0.5 Å , 2.3 ± 0.38 Å , and 2.4 ± 0.3 Å , in the ALAS-
WTchA, ALAS-WTchB, and ALAS-MTchB monomers, respectively. These distances were 
closer to the results found for the HemA-WT. 
 
The ALAS2 systems, especially the ALAS-MTchA, followed different patterns. Although 
the trajectories of changes in the minimal distances between the active site loop and M333 for 
ALAS-WTchA, ALAS-WTchB, and ALAS-MTchB were similar to the trajectories observed in the 
HemA systems, the ALAS-WTchA had a distinct minimal change trajectory with the greatest 
values occurring at 100 – 150 ns and then returning to the minimal distance levels of other 
ALAS2 monomers (Figure 3.6C). Nevertheless, a considerably greater value associated with 
the minimal distance between the active site loop and M333 was observed for ALAS-MTchA at 
50 – 80 ns. Succinctly, the minimal distances averaged over the entire trajectories were 2.5Å , 
3.1Å , 2.4Å , and 2.4Å  for ALAS-WTchA, ALAS-MTchA, ALAS-WTchB, and ALAS-MTchB, 
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respectively. Curiously, HemA-MT and ALAS-MTchA showed similar average distances (Figure 
3.6B vs. D). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7 Principal component analysis (PCA) of structures populated by the mALAS2 
monomers (wild type and hepta-mutant) during the MD simulation followed by the 
hierarchical k-means clustering (k=4) (Continued on Next Page).  
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Figure 3.7 Principal component analysis (PCA) of structures populated by the mALAS2 
monomers (wild type and hepta-mutant) during the MD simulation followed by the 
hierarchical k-means clustering (k=4). A. Principal component (PC) space for the PCA-
generated principal components PC1 and PC2 (a), PC2 and PC3 (b), and PC3 and PC2 (c). 
In these plots, data for clusters 1, 2, 3, and 4 are shown as pink, cyan, green, and purple 
circles, respectively. Plot d represents the dependence of the proportion of the variance on 
Eigenvalue rank and indicates that the PCA-generated PC1 and PC2 are characterized by 
the 66.8% variance coverage. B. Hierarchical clustering of structures populated by the ALAS-
WT and ALAS-MT monomers generated four clusters (1, 2, 3, and 4) shown in pink, cyan, 
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green, and purple color, respectively. Cluster 3 (green) is mostly occupied by the 
representatives of the ALAS-MTchA structures and includes just two ALAS-WTchB structures. 
C. Representative structures of the C-terminal region containing the affected loop and β13 
selected and superimposed for each cluster. Cluster 3 (green) showed the presence of the 
new β-strand at the affected loop. D. Analysis of the number of hydrogen bonds within the 
PCA-generated clusters revealed that the greatest number of hydrogen bonds (2.9 ± 0.8) is 
found in cluster 3, whereas for  cluster 1, cluster 2, and cluster 4, these numbers were 1.3 ± 
1.0, 1.3 ± 1.3, and 0.20 ± 0.45, respectively.  
 
 
3.2.6 Active Site Loop β-strand Formation Discovery in the Variant 
Using principal component analysis (PCA), followed by k-means hierarchical clustering, 
we grouped the ALAS2 monomer structures into four clusters from principal components 1 and 
2 (Figure 3.7A). All ALAS-WTchA and ALAS-MTchB structures were included into cluster 1. 
ALAS-WTchB structures were separated into cluster 2, 3, and 4. All of ALAS-MTchA structures 
occupied cluster 3, and there were only three ALAS-WTchB structures (Figure 3.7B). 
Based on the results regarding the dynamics of the hydrogen bonds in the mutated 
active site loop and strand β13, we decided to focus on this loop in the different clusters (Figure 
3.7C). Although cluster 1 showed one β-strand in the mutated loop from superimposed 
structures, cluster 3 showed most of the structures form β-strand in the mutated loop. 
To verify greater chances of β-strand formations in cluster 3, which have all of the ALAS-
MTchA structures, we measured number of hydrogen bonds between the mutated active site 
loop and the β13-strand (Figure 3.7D). Mean values for the number of hydrogen bonds in 
clusters 1 to 4 were 1.3, 1.3, 2.9, and 0.2, respectively. This obviously showed that there were 
more hydrogen bonds within the area of interest in cluster 3. 
3.3 Discussion 
Solving the crystal structure of the R. capsulatus HemA provided critical insight into the 
structural features and organization of ALAS [136]. In fact, analysis of the crystallographic 
structures of R. capsulatus ALAS (holoenzyme and substrate-bound enzyme) along with the 
characterization of the kinetic mechanism of mALAS2 led us [131, 137, 138, 142] and others 
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[136] to predict the dynamic nature of ALAS, particularly that of the active site loop, and propose 
its role in determining the overall ALAS reaction rate. Despite the gained structural information 
not being sufficient to provide the structural basis for the enhanced enzymatic activity 
associated with the mALAS2 hepta-variant, it did unveil the active site loop as the site 
undergoing the major protein conformational change [136]. Targeting, through shuffling and 
saturation mutagenesis, the non-conserved residues in the mALAS2 loop, yielded “hyperactive” 
mALAS2 variants, some of which with such an increased rate for the proposed closed to open 
conformational transition that product dissociation from the enzyme was no longer the reaction 
rate-limiting step as in the case of wild type mALAS2 [138]. Results from this study 
substantiated our proposal that conformational dynamics control the rate of product (ALA) 
release [137, 142] and led us to postulate that ALAS is allosterically regulated [131, 138], but 
how the mALAS2 active site loop mutations induced changes in the structural and dynamic 
properties of the enzyme remained elusive. With the present work, we aimed to uncover the 
hidden basis for these changes by testing our hypothesis that the mALAS2 hepta-variant 
undergoes a faster closed-to-open conformation transition than wild-type mALAS2.  
MD simulations of the conformational progression of mALAS2 and respective hepta-
variant indicated that the mALAS2 active site loop harboring the simultaneous seven amino acid 
mutations was less flexible than the wild type loop. This result also supported intrinsic disorder 
predictions (Figure 3.2B). The lowered flexibility inherent to the mutated active site loop was 
most probably due to the triggering of a loop-to-β-strand transition, an observation supported by 
the results of intrinsic disorder analysis  and MD simulation (Figures 3.2A and 4-6). Indeed, this 
new β-strand with two other neighboring β-strands formed an anti-parallel, three β-stranded 
structure, which might have contributed to the increased rigidity of the active site loop and 
destabilization of the mALAS2 closed conformation. Thus, in a plausible scenario, the loop-to-β 
-strand structural transition might cause mALAS2 to progress to the open conformation much 
more rapidly and stabilize this open conformational state. A similar situation was reported for the 
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tyrosyl-tRNA synthetase from Mycobacterium tuberculosis (MtTyrRS) [143]. Here, the MD 
analysis of the effect of different substrates, such as tyrosine, ATP, and the tyrosyl-adenylate 
intermediate on the conformational mobility of the MtTyrRS catalytic KFGKS loop, revealed that 
the this loop can adopt different stable conformations depending on the type of bound substrate 
and that the closed state of MtTyrRS is stabilized by dynamic formation of two antiparallel β-
strands at flanking ends that are responsible for holding the KFGKS fragment inside the active 
center [143]. Analogously, in the TyrRS from Thermus thermophiles [144] and from 
Staphylococcus aureus [145], the active site KMSKS loop was shown to adopt different 
conformations depending on the type of the substrate bound to the active site pocket. It was 
also reported that ligand binding was able to affect dynamics of the active site loop in 
triosephosphate isomerase [146]. 
Our computational analysis revealed an interesting correlation between the hepta-
mutation-induced changes in the intrinsic disorder propensities and the dynamic behavior of 
human and bacterial ALAS. In fact, although the hepta-variant of mALAS2 was characterized by 
a decreased intrinsic disorder propensity in the active site loop, similar mutations introduced to 
the bacterial enzyme, HemA, resulted in a noticeable increase in its local disorder propensity 
(Figure 3.2). Consistent with these predictions, the mutated HemA active site loop showed a 
greater flexibility than that of the wild type protein. Curiously, there was also a remarkable 
difference in the mutation-induced changes of the dynamic behavior of the mALAS2 protomers. 
Here, although in agreement with disorder predictions, the dynamics of the ALAS-MTchB was 
unmistakably reduced in comparison with the dynamics of the ALAS-WTchB form, while the 
dynamics of the mutated loop in the ALAS-MTchA was enhanced in comparison to that of the 
ALAS-WTchA form, evidently indicating the non-equivalence or asymmetry of the subunits in 
the dimeric enzyme. Functional non-equivalence or asymmetry of the identical protomers was 
earlier reported for several homodimeric enzymes, such as glutamate-1-semialdehyde 
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aminomutase [147], Vibrio alkaline phosphatase [148], O-acetylserine sulfhydrylase isozyme B 
from Escherichia coli [149], and alkaline phosphatase from E. coli [150], to name a few. 
It is clear that such ALAS subunit asymmetry is not caused by the mutations, since both 
proteoforms in the dimeric mALAS2 possessed the same seven mutations. It is therefore likely 
that the difference in dynamics between the mutated protomers originates from allosteric 
perturbations caused by the dimer formation. Previously, we demonstrated functional 
asymmetry for the active sites of an engineered, single polypeptide chain, mALAS2 dimer [151]. 
When the catalytic lysine in one of the active sites was mutated to render a single chain 
mALAS2 dimer with only one functionally active site, the amount of product formed during the 
first turnover was identical regardless of which of the two active sites harbored the mutation. 
However, the kcat values differed according to the mutated site, hence indicating that the two 
active sites made asymmetrical steady-state contributions to the activity of the mALAS2 single 
chain dimer. Because the construction of the single polypeptide chain mALAS2 dimer involved 
the inclusion of a two-amino acid linker between the two ALAS chains, we could only conclude 
that the functional asymmetry of the active sites resulted from this introduced intermolecular 
strain which, in turn, altered the protein conformational flexibility and rate of product release [32].  
It is now tempting to speculate that the differences in the dynamic behavior of the 
mutated mALAS2 (hepta-variant) protoforms within the dimeric structure could be related to the 
allosterically-regulated timing of enzymatic activity of this protein. For a dimer with two identical 
active sites, total enzymatic activity (i.e., activity originating from both sites) can be uncontrolled 
(when both sites act stochastically and independently from each other) or allosterically 
controlled (when the occupation of or release from one active site leads to perturbations in the 
function of the other active site). In this way, two active sites of a dimer can act in opposite 
phases, with closure of one of the active sites promoting the opening of the other.  Significantly, 
asymmetry in structure and active site reactivity has been detected in glutamate-1-
semialdehyde aminomutase (GSAM), a PLP-dependent enzyme, which catalyzes the 
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isomerization of glutamate-1-semialdehyde into ALA in plants, green algae and most bacteria 
[147, 152, 153]. Further, asymmetry was also observed in a mobile loop controlling active site 
access and dissociation of reaction intermediates [147, 153]. By undergoing a conformational 
change, the loop can simultaneously be closed and covering the active site in one subunit and 
open and exposing the active site in the other. Actually, the loop cannot be in a closed 
conformation in both GSAM subunits at the same time [153]. Of relevance, to assume the 
closed conformation, the active site loop requires a “β-sheet-to-α-helix” transition [153], 
evocative of the “loop-to-β-strand” transition detected in the MD simulation analysis of the 
hepta-variant conformational evolution to a more open state. Unlike ALAS, GSAM functions as 
an aminotransferase, and thus, during its catalytic cycle, the cofactor interchanges between the 
pyridoxamine 5’-phosphate (PMP) and the aldehyde (PLP) forms. The reduction of the PLP 
Schiff base linkage to GSAM by NaBH3CN has been instrumental in the identification of the 
asymmetry of the active site loop between the GSAM subunits in solution [147, 152], as proven 
with the biphasic kinetic trace for the reduction of GSAM in which both subunits have the 
cofactor in the PLP form [147]. While we have not identified asymmetry in ALAS active site 
reactivity in solution [154], to “capture” the asymmetry of the active site loop conformation 
between the two ALAS subunits in solution might prove to be technically challenging. But 
certainly, the possibility of allosterically controlled inter-subunit communication in ALAS2 as yet 
another mechanism of regulation of the first step of heme synthesis in the precursor erythroid 
cell cannot be ruled out. 
3.4 Methods 
3.4.1 Sequence preparation and intrinsic disorder prediction 
Sequence alignment was performed for the R. capsulatus HemA (UniProt ID P18079) 
and Mus musculus ALAS2 (UniProt ID P08680) sequences, using UniProt 2016_07 embedded 
Clustal Omega 1.2.2 [106, 107]. The aligned sequence and remaining C-terminal region of 
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ALAS2 were obtained and preserved (UniProt ID P08680 residues 143-587 = mature mALAS2 
residues 65-509), resulting in the removal of the non-conserved N-terminal region of mature 
mALAS2. Seven simultaneous variations were introduced in the loop region (UniProt ID P08680 
residues Y500-R517 = mature mALAS2 residues Y422-R439) of the conserved fragment of 
mALAS2 according to the Lendrihas et al. study [138]. Additionally, the same variations were 
introduced to the sequence-aligned corresponding regions of R. capsulatus HemA (residues 
Y357-E371). The intrinsic disorder scores for the wild type enzyme and the resulting variant 
sequences were measured using PONDR®  VLXT predictor [57]. 
 
3.4.2 Murine ALAS2 structure preparation for MD study 
The I-TASSER web algorithm was applied for homology modeling [155]. The closed 
conformation of R. capsulatus HemA (PDB 2BWN chain D) was used as a template [136], and 
the wild type mALAS2 sequence (UniProt P08680 residues 143 - 587) was uploaded. The best 
model from the I-TASSER output was structurally aligned with the PDB 2BWN chain D, and the 
LLP residue (N'-pyridoxyl-lysine-5'-monophosphate) was obtained from the frame PDB file, 
using PyMol 1.3, in order to prepare the wild type mALAS2 structure. Seven variations were 
introduced using the PyMol 1.3 mutagenesis module, and suitable rotamers were chosen for 
each mutated residue. For the HemA structure, the PDB 2BWN chain D was converted to PQR 
format, so the hydrogen atoms could be added using the PDB2PQR web algorithm and the wild 
type structure prepared [156]. The mutagenesis module in Pymol 1.3 was also applied to 
prepare the variant structure. LLP residue parameters were obtained using CGenFF [113]. 
 
3.4.3 MD simulations 
For all MD simulations, the Gromacs 5.0.4 double precision version installed with the 
FFTW 3.3.4 library, and CHARMM 36 force-field, provided by the MacKerell Lab homepage 
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(http://mackerell.umaryland.edu/charmm_ff.shtml) were used [114, 116, 157]. A truncated 
octahedron box with a periodic boundary condition was constructed with a buffering area 
thickness of 1.2 nm. For explicit water models in the MD simulation systems, ~35,010, and 
~17,620 TIP3P water molecules were constructed for mALAS2 systems (wild-type mALAS2 and 
variant, thereafter referred to as: WT and MT) and HemA systems (wild-type R. capsulatus 
ALAS2 and variant, thereafter referred to as: WT and MT), respectively. Then, ~150 mM of K+ 
and Cl- ions were added to the systems. The number of ions was adjusted to neutralize the 
system. Energy minimization using the steepest descent method was performed until the 
maximum force was less than 1000 kJ mol-1 nm-1, with an initial step size of 0.01 nm. 
During the heating steps, 2ps (1000 steps with Δt = 2fs) of each short canonical (NVT) 
ensemble-position-restrained MD simulations were performed at three different temperatures: 
100K, 200K, and 288K (288K was applied as an experimental condition as in Lendrihas et al. 
2010 [138]). At each NVT condition, velocities were generated according to the Maxwell 
distribution. A position restraint constant of 1000 kJ mol-1 nm-2 was applied to all heavy atoms, 
and a V-rescale was used to control temperature [158]. The bond lengths with H-atoms were 
constrained using the LINCS method [159]. For long-range electrostatics calculations, the 
Particle mesh Ewald method (PME) was used [121, 122]. The Verlet cut-off scheme was used 
every 10fs to update the neighbor list [160]. The electrostatic cut-off and van der Waals cutoff 
were set to be 1.2 nm. 
Equilibration steps were performed with three 1ns isothermal-isobaric (NPT) ensemble 
MD simulations using three different position restraint constants: 1000 kJ mol-1 nm-2, 100 kJ mol-
1 nm-2, 10 kJ mol-1 nm-2. At each NPT condition, temperature was maintained at 288K, and 
velocities were generated from previous steps. With exception of the pressure control, all 
parameters were maintained the same as in the heating steps. Parrinello-Rahman barostat was 
applied to maintain the pressure of the system at 1 bar [123, 124]. 
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During the production run, all 200 ns MD simulations were performed with the NPT 
ensemble without position restraints. With exception of the position restraint condition, all 
parameters were the same as in the equilibration step. During each production step, 2001 
frames were collected with the 100 ps intervals, and the corresponding trajectories were stored 
for further analysis. 
 
3.4.4 MD simulation analysis 
We analyzed 2001 frames of each of the following MD simulation sets: wild type HemA 
(HemA-WT), HemA hepta-variant (HemA-MT), wild type mALAS2 (ALAS-WT), and mALAS2 
hepta-variant (ALAS-MT). In the cases of mALAS2 WT and hepta-variant, we separately 
analyzed the monomer chains A and B. Thus, a total of four MD simulation sets - ALAS-WTchA, 
ALAS-MTchA, ALAS-WTchB, and ALAS-MTchB – were conducted for both wild type mALAS2 
and mALAS2 hepta-variant. 
Protein backbone root-mean squared deviations (RMSD) and root-mean squared 
fluctuations (RMSF) in the six MD simulation trajectory sets were calculated using Gromacs 
5.0.4 ‘rmsdist’, and ‘rmsf’ functions after fitting at each reference structure. During the fitting, the 
backbone atom coordinates for the HemA residues 19-397 and mALAS2 residues 161-540 of 
the energy minimized structures were used as reference structure, except for the RMSD 
calculation of the total protein backbone. RMSD calculation of the total protein backbone was 
done after fitting at each energy minimized structure backbone. For the RMSD calculations, the 
energy minimized backbone structure of every trajectory was used as a reference structure. 
From the first RMSD, and RMSF calculations, we analyzed the data focusing on the 
HemA residues 19-397 and the mALAS2 residues 161-540. We applied Gromacs 5.0.4 ‘hbond’, 
and ‘mindist’ functions to measure the number of hydrogen bonds between the conserved β13 
strand (HemA R372-F375, mALAS2 L515-L518) and the active site loop (HemA Y357-E371, 
mALAS2 Y500-E514) and the distance between the conserved methionine (HemA M190, 
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ALAS2 M333) and the active site loop (HemA Y357-E371, ALAS2 Y500-E514). These regions 
were determined based on their structural homology with HemA [136]. 
To characterize the structural differences among the mALAS2 chains of WT and hepta-
variant, we performed principal component analysis (PCA) followed by k-means clustering after 
clustering of each trajectory. We obtained clusters using Gromacs 5.0.4 ‘cluster’ function based 
on each energy minimized backbone structure (HemA residues 19-397 and mALAS2 residues 
161-540) without the tail, and chose some representative structures of each cluster when the 
number of frames at each cluster was greater than 9. The chosen backbone coordinates of all 
representative structures were combined into one file. Then, this was analyzed using Bio3D 2.2-
2 module installed in R 3.2.1 [161].  
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CHAPTER 4. TROPONIN VARIANTS IN CARDIOMYOPATHY 
 
Note to reader 
 Part of this chapter were published in Na I, Kong M, Straight S, Pinto J, Uversky V. 2016 
Troponins, intrinsic disorder, and cardiomyopathy. Biological Chemistry. 397(8):731-51. 
DOI: 10.1515/hsz-2015-0303, and have been reproduced under copyright permission by 
Copyright Clearance Center (Appendix A, D). 
 
4.1 Introduction 
4.1.1 Cardiomyopathy: Hypertrophic Cardiomyopathy (HCM) and Dilated 
Cardiomyopathy (DCM) 
 Cardiomyopathy is a malfunction of the heart muscle and it encompasses groups of 
heart structural changes caused by a variety of disorders or genetic alterations. Unfortunately, 
some of the genetic causes leading to this disease are still not fully understood and the etiology 
of the cardiomyopathy remains vastly idiopathic [162]. This has prompted us to investigate this 
disease in light of the phenomenon of protein intrinsic disorder and to look at the effects of 
disease-related mutations on protein disorder propensities and functionalities paying special 
attention to protein-protein interactions and posttranslational modifications (PTMs). The two 
most common types of inherited cardiomyopathy are hypertrophic cardiomyopathy (HCM) and 
dilated cardiomyopathy (DCM). 
 HCM is characterized by abnormal thickening of the heart wall, particularly affecting the 
left ventricle. Histologically, myocyte fibers of the HCM heart are hypertrophied and irregularly 
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organized [163, 164]. It is estimated that one in 500 people can be affected by HCM [165, 166]. 
Most often, HCM is developed due to the genetic aberrations (mutations) in one of many 
sarcomeric genes encoding various myocardial contractile proteins, such as myosin heavy 
chain (MYH7), myosin-binding protein C (MYBPC3), cardiac troponin C (TnC, gene name 
TNNC1), cardiac troponin T (TnT, gene name TNNT2), and cardiac troponin I (TnI, gene name 
TNNI3) among others [164, 167]. The majority of HCM cases show autosomal dominant 
inheritance characteristics [168]. Clinically, HCM patients can remain asymptomatic throughout 
their life and free from any associated complications [169]. The disproportionate thickening of 
the left ventricular wall without chamber dilation leads to diastolic dysfunction and decreased 
cardiac output. Thickened walls also impair the ability of heart to conduct electrical signal, and, 
as a result, ventricular arrhythmia may arise in response to sports training [170]. This makes 
HCM, the most common cause of sudden death in young population [164]. 
DCM is characterized by the left ventricular systolic dysfunction secondary to the left 
ventricular dilation, which increases its mass and volume. Some patients also present with right 
ventricular dilation and dysfunction and left ventricular diastolic dysfunction [171]. DCM is 
commonly subdivided into ischemic or non-ischemic. Common non-ischemic etiologies of DCM 
includes: coxsackievirus infection, alcohol abuse, some drugs (e.g. doxorubicin), pregnancy, 
and hemochromatosis. When all identifiable causes are excluded, the patient is diagnosed with 
idiopathic DCM [172, 173]; unfortunately, most DCM cases are idiopathic in etiology. It is 
believed that two out of three children with DCM have the idiopathic form of the disease [174]. 
Clinically, DCM patients show systolic dysfunction and predisposition to congestive heart failure. 
Patients may show complications, such as mitral and tricuspid valve regurgitation and 
arrhythmia [171, 175]. As the disease worsens, a heart transplant becomes necessary in severe 
cases [171]. 
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4.1.2 Troponin Complex and Cardiomyopathy 
Troponin complex is the key component that regulates the on and off switch of cardiac 
muscle contraction. It is connected to the thin filament and consists of TnT that interacts with 
tropomyosin (Tm), TnC that binds Ca2+, and TnI that inhibits the ATPase activity of actomyosin 
complex. Cardiac muscle contraction is initiated by the increase in intracellular Ca2+ levels and 
binding of this ion to TnC. However, the three troponin subunits work together as a complex, the 
structure of which changes conformation after binding of Ca2+. This allows myosin to interact 
with actin, with consumption of ATP, allowing muscle contraction [176]. 
It is known that mutations in genes encoding sarcomere proteins accounts for most of 
the HCM and DCM cases [177, 178]. Recent investigations have also shown that the 
physiological effects of troponin mutations associated with HCM and DCM are different. 
Impaired relaxation with significant increase in Ca2+ sensitivity of force production has been 
shown for HCM mutations. In contrast, DCM mutations showed decreased Ca2+ sensitivity of 
force production [177, 179]. The key regulator of cardiac muscle contraction is the intracellular 
Ca2+ level of the myocyte. When the intracellular Ca2+ concentration is high (~10-5 M), the 
muscle contracts and when the concentration is low (~10-7 M), muscle relaxes. At the same 
intracellular Ca2+ concentration, increased Ca2+ sensitivity generates more muscle tension and 
the muscle remains hyper-contracted and conversely, decreased Ca2+ sensitivity generates 
reduced muscle tension [180]. There is strong correlation between the mutations in each 
troponin subunit and the increase or decrease in the Ca2+ sensitivity in HCM and DCM, 
respectively. We can clinically relate this to the hyper-contractile characteristic in HCM and the 
systolic dysfunction in DCM [177, 180]. 
 
4.1.3 Connection with Protein Intrinsic Disorder 
 Human cardiac troponin is a highly dynamic complex with structurally different 
subdomains connected by flexible linkers [181]. This dynamic nature of the troponin complex 
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suggests that its structure and function can be controlled by some features related to the 
phenomenon of protein intrinsic disorder. However, the exact role of intrinsic disorder in 
structure and function of this important protein complex as well as the effects of the 
cardiomyopathy-related mutation on the disorder propensity of its subunits have not been 
studied as of yet. To fill this gap and to find possible links among TnC, TnT, and TnI mutations 
and HCM and DCM, we computationally analyzed how intrinsic disorder propensities of the 
troponin subunits and their disorder-based functionalities are affected by the known mutations in 
these proteins. 
The protein functionality is believed to be linked to its unique, stable, three-dimensional 
structure. However, it is recognized now that the universe of functional proteins contains both 
ordered and intrinsically disordered entities, and therefore biologically active proteins can be 
ordered, partially-ordered, and completely disordered [182, 183]. Each protein varies in its 
disorder content and flexibility, and this variability is determined by the peculiarities of protein 
amino acid sequences [182]. Intrinsic disorder accelerates interaction of proteins with their 
partners, defines functionality of chaperones, determines the predisposition of proteins for 
posttranslational modifications, is correlated with alternative splicing of RNA, and plays a role in 
various activities of DNA- and RNA-interacting proteins [184]. Furthermore, intrinsically 
disordered proteins (IDPs) and intrinsically disordered protein regions (IDPRs) are promiscuous 
binders and play various important roles in protein complexes [184, 185]. Although IDP and 
IDPRs are normally under very tight control, dysfunction on this control may result in the altered 
structure, perturbed functionality, and eventually progression to various pathologic conditions 
[41]. Previous research has identified several disordered regions in proteins involved in the 
troponin complex [186-189]. 
 
4.1.4 Research Purpose, and Approach 
The goal of this study was to investigate the association of the identified IDPRs in 
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troponins with HCM and DCM. In other words, we hypothesized that some HCM- and DCM- 
associated mutations in TnC, TnT, and TnI could cause significant changes in the intrinsic 
disorder predisposition and/or binding propensity of proteins of the troponin complex. To test 
this hypothesis, we evaluated and compared the intrinsic disorder scores and binding 
propensities of the wild-type and disease-related variants of TnC, TnT, and TnI. Then, to 
investigate whether the mutation-induced changes in the intrinsic disorder scores or binding 
propensities are significantly enriched in the HCM- or DCM-associated cases, Fisher’s exact 
test was applied. As this analysis did not revealed any meaningful relation between the HCM 
association and the score change patterns, the χ2 goodness of fit test was applied to determine 
whether there is a difference in the proportions of smaller and greater scores causing variants. 
We showed that except to the TnC variations, mutations causing a decrease in the disorder 
score were significantly more abundant in both diseases than mutations leading to the increase 
in the disorder score. These observations suggested that the variants causing decrease in the 
intrinsic disorder score had greater propensity to cause diseases. Therefore, it is likely that 
those disease-causing mutations in troponins, which are associated with the decreased local 
protein flexibility could trigger a whole plethora of functional changes ranging from muscle 
regulation to gene expression regulation. Furthermore, for the first time we identified the IDPRs 
in each of the troponin subunits, which can serve as the basis for the understanding of the roles 
of these regions in muscle regulation, as well as in posttranslational modifications of cardiac 
troponin. 
 
4.2 Results 
4.2.1 Intrinsic Disorder Changes 
 Table 4.1 lists TnC, TnI, and TnT disease-related variants analyzed in our study and 
shows changes introduced by these mutations on the PONDR-FIT disorder scores of these 
proteins at the mutation point. Table 4.1 illustrates that the vast majority of SNPs cause local 
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decrease in the disorder propensity, and some mutations have very noticeable effects 
(evaluated as a difference between the disorder scores calculated for the mutant and wild type 
proteins) on the local disorder propensity. We used a difference threshold of ± 0.100 as the 
measure of the significant effect of each mutation on disorder score of the residue. For example, 
in TnC, the largest differences are introduced by disease- related mutations M103I (-0.177) and 
D75Y (-0.171), and by mutations found in a healthy population I119T (+0.151), R102C (-0.112), 
D132N (-0.110), and D88N (-0.107). The D75Y mutation was present in association with the 
E59D mutation (E59D/D75Y), thus our data suggest that the D75Y might be the dominant 
variant. In TnT, the most influence is shown by the disease-related mutations R92W (-0.377), 
R94C (-0.253), R278C (-0.227), N271I (-0.209), R113W (-0.202), R286C (-0.147), R92L (-
0.114), and R94L (-0.124) mutations M95V (-0.141), and R278H (-0.106) found in a healthy 
population. Finally, in TnI, the most disturbing disease-related mutations are R162W (-0.135) 
and L144P (0.102), whereas similar mutations found in a healthy population are R186W (-
0.345), R192C (-0.338), R79C (-0.186), R103C (-0.185), R192H (-0.170), R145W (-0.131), 
R103L (-0.121), H101Y (-0.113), and V176G (0.138). Values in brackets correspond to the 
residue-specific differences between the disorder scores of a given mutant and a wild type 
protein calculated at the mutation site. Negative numbers in brackets indicate mutations causing 
noticeable decrease in local disorder propensity, whereas positive numbers correspond to 
mutations leading to the increase in disorder score. However, Table 4.1 also shows that many 
mutations both disease-causing and disease-neutral have very marginal effects on the local 
disorder propensity. The presence of noticeable variability in the effects of different mutations on 
the disorder propensities of TnC, TnT, and TnI is further illustrated by Figure 4.1 where the 
disorder profiles generated for these proteins by PONDR-FIT of per-residue disorder 
predisposition are shown. 
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Table 4.1 Major characteristics of mutants of human cardiac TnC, TnI, and TnT. Red and blue color 
indicate entries for which differences between the disorder scores calculated for the mutant and wild type 
proteins exceed the +/-0.100 threshold. “Red” entries are variants that are significantly more disordered 
than the wild type protein, whereas “blue” entries show variants that are significantly less disordered 
(Continued on Next Page).  
Variant 
name 
PONDR-FIT 
disorder score at 
mutation point 
Δ 
(variant
–WT) 
Disease 
Variant 
name 
PONDR-FIT 
disorder score at 
mutation point 
Δ 
(variant
–WT) 
Disease 
Wild type Variant Wild type Variant 
Human cardiac troponin C (TnC, UniProt ID: P63316, Gene ID: TNNC1) 
A8V 0.635 0.540 -0.095 HCM G159D 0.905 0.933 0.028 DCM 
A31S 0.205 0.221 0.016 HCM I148V 0.576 0.550 -0.026 DCM 
C84Y 0.552 0.499 -0.053 HCM L29Q 0.158 0.153 -0.005 HCM 
D75Y 0.711 0.540 -0.171 DCM M103I 0.368 0.191 -0.177 DCM 
D145E 0.629 0.618 -0.011 HCM Q50R 0.454 0.430 -0.024 DCM 
E59D 0.796 0.801 0.005 DCM Y5H 0.889 0.935 0.046 DCM 
E134D 0.678 0.683 0.005 HCM      
Human cadiac troponin T (TnT, UniProt ID: P45379-6, Gene ID: TNNT2) 
A104V 0.770 0.676 -0.094 HCM R92W 0.777 0.400 -0.377 HCM 
A172S 0.753 0.749 -0.004 DCM R94C 0.763 0.510 -0.253 HCM 
D86A 0.784 0.736 -0.048 HCM R113W 0.789 0.587 -0.202 DCM 
D270N 0.609 0.649 0.040 DCM R130C 0.913 0.879 -0.034 HCM 
E83K 0.761 0.810 0.049 HCM R131G 0.912 0.894 -0.018 DCM 
E163K 0.839 0.843 0.004 DCM R134G 0.914 0.903 -0.011 DCM 
E163R 0.839 0.859 0.020 DCM R141W 0.952 0.949 -0.003 DCM 
E244D 0.193 0.188 -0.005 HCM R151C 0.915 0.885 -0.030 DCM 
F110I 0.788 0.795 0.007 HCM R159Q 0.905 0.904 -0.001 DCM 
F110L 0.788 0.82 0.032 HCM R173Q 0.731 0.709 -0.022 DCM 
F110V 0.788 0.784 -0.004 HCM R205L 0.855 0.843 -0.012 DCM 
I79N 0.814 0.819 0.005 HCM R205W 0.855 0.823 -0.032 DCM 
K97N 0.732 0.74 0.008 HCM R278C 0.716 0.489 -0.227 HCM 
K247R 0.248 0.192 -0.056 HCM R278P 0.716 0.653 -0.063 HCM 
K273E 0.688 0.628 -0.060 HCM R286C 0.916 0.769 -0.147 HCM 
N271I 0.628 0.419 -0.209 HCM R286H 0.916 0.868 -0.048 HCM 
R92L 0.777 0.663 -0.114 HCM S69F 0.770 0.725 -0.045 HCM 
R92Q 0.777 0.768 -0.009 HCM S179F 0.653 0.648 -0.005 HCM 
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Table 4.1 Major characteristics of mutants of human cardiac TnC, TnI, and TnT. Red and blue color 
indicate entries for which differences between the disorder scores calculated for the mutant and wild type 
proteins exceed the +/-0.100 threshold. “Red” entries are variants that are significantly more disordered 
than the wild type protein, whereas “blue” entries show variants that are significantly less disordered. 
 
Variant 
name 
PONDR-FIT 
disorder score at 
mutation point 
Δ 
(variant
–WT) 
Disease 
Variant 
name 
PONDR-FIT 
disorder score at 
mutation point 
Δ 
(variant
–WT) 
Disease 
Wild type Variant Wild type Variant 
Human cardiac troponin I (TnI, UniProt ID: P19429, Gene ID: TNNI3) 
A2V 0.999 0.998 -0.001 DCM L198V 0.798 0.795 -0.003 HCM 
A157V 0.267 0.242 -0.025 HCM P82S 0.543 0.614 0.071 HCM 
D127Y 0.222 0.255 0.033 HCM R21C 0.877 0.792 -0.085 HCM 
D196N 0.726 0.730 0.004 HCM R141Q 0.284 0.221 -0.063 HCM 
E202G 0.963 0.956 -0.007 HCM R145G 0.255 0.193 -0.062 HCM 
G203R 0.960 0.972 0.012 HCM R145Q 0.255 0.192 -0.063 HCM 
G203S 0.960 0.969 0.009 HCM R162Q 0.334 0.246 -0.088 HCM 
H34Q 0.836 0.855 0.019 HCM R162W 0.334 0.199 -0.135 HCM 
I195M 0.737 0.836 0.099 HCM R186Q 0.691 0.613 -0.078 HCM 
K183E 0.632 0.599 -0.033 HCM R204C 0.950 0.880 -0.070 HCM 
K206Q 0.968 0.958 -0.010 HCM R204H 0.950 0.921 -0.029 HCM 
L144P 0.267 0.369 0.102 HCM S166F 0.374 0.349 -0.025 HCM 
L198P 0.798 0.836 0.038 HCM S199N 0.812 0.830 0.018 HCM 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 Effects of disease-variations on the intrinsic disorder of troponins 
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Figure 4.1 Effects of disease-variations on the intrinsic disorder of troponins. A-B TnC 
(Gene ID: TNNC1), C-D TnT (Gene ID: TNNT2), E-F TnI (Gene ID: TNNI3) by PONDR-FIT 
intrinsic disorder score. 
 
 Plotting the intrinsic disorder scores of the variants and wild type troponins as described 
in the Methods (Figure 4.1) revealed that the disease-associated mutations can cause diverse 
changes in the disorder distribution profiles of troponins. Comparison of the corresponding plots 
for the TnC, TnT, and TnI revealed that the TnT showed the most dynamic patterns of intrinsic 
disorder scores (Figure 4.1). However, disorder plots shown in Figures 4.1 does not allow direct 
evaluation of the significance of changes in the disorder propensities caused by mutations. To 
address this issue, we conducted statistical analysis as described in the Methods section. 
 This analysis revealed that there was no strong evidence that the HCM-related 
mutations can generate oriented (or directed) changes in the intrinsic disorder propensity; i.e. 
changes where the disorder levels in the mutant proteins become systematically smaller or 
greater than the disorder levels in the corresponding wild type proteins, not only for the entire 
troponin complex, but also for the individual troponins (Table 4.2). Although it was not tested 
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specifically in our computational analysis, it could be inferred from the Fisher’s exact tests' p-
values that there was also no greater proportion of lower intrinsic disorder causing mutations in 
DCM cases. 
Table 4.2 1-Tailed Fisher’s exact test p-values for intrinsic disorder & HCM association. We tested 
the significance of the fractions of the HCM-related variants with intrinsic disorder scores smaller than the 
corresponding values calculated for the wild type proteins. 
 
Category PONDR-FIT PONDR-VLXT PONDR-VSL2 
Troponin complex 0.6825 0.8531 0.6756 
TnC 0.9121 0.7165 0.8788 
TnT 0.5286 0.9871 0.5897 
TnI 1 1 1 
 
 However, there was a significant correlation between the direction of the mutation-
induced changes in the intrinsic disorder predisposition and the propensity of the mutations to 
induce either HCM or DCM. In fact, Table 3 shows that mutations causing reduction of the 
intrinsic disorder score are associated with the greater predisposition for these diseases. At the 
level of individual proteins, only TnC showed no significantly different proportions of mutations 
causing increase or decrease of the disorder scores, whereas TnT, TnI, and troponin complex 
showed significantly different proportions of such mutations. Furthermore, troponin complex, 
TnT, and TnI showed greater association with disease when mutations caused the decrease in 
the intrinsic disorder propensity. Therefore, these data suggest that in comparison with the TnC, 
the intrinsic disorder characteristics of the TnT and TnI are more sensitive to the disease-
causing mutations. Overall, this analysis revealed that except to the TnC variations, mutations 
causing decrease in the disorder score were significantly more abundant in both diseases than 
mutations leading to the increase in the disorder score. 
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Table 4.3 Goodness of fit test p-values to find association between intrinsic disorder & both of 
disease types. We tested proportional differences between the variants with smaller and greater intrinsic 
disorder scores causing both types of diseases (HCM & DCM). 
 
Category PONDR-FIT PONDR-VLXT PONDR-VSL2 
Troponin complex 0.0007891 0.000407 7.52E-06 
TnC 0.3657 1 0.5637 
TnT 0.00604 0.007661 3.96E-05 
TnI 0.06057 0.004267 0.02181 
 
 
4.2.2 Binding Propensity Changes 
 Figure 4.2 illustrates the differences between the ability of the HCM- or DCM-causing 
mutations to induce significant changes in binding propensity of the corresponding proteins 
evaluated by the three computational tools for finding disorder-based potential binding sites. 
Among these three algorithms, MoRFpred provided a relatively smaller number of significant 
cases. ANCHOR and DisoRDPbind predictions for the TnT, and TnI showed relatively greater 
proportions of HCM cases than TnC. In the DCM cases, TnI showed relatively small counts of 
mutations causing significant changes in its binding propensity. 
 To further investigate this phenomenon, the variants were statistically analyzed as 
described in the Methods section. Results of these analyses are summarized in Tables 4.4, and 
4.5. These analyses revealed that there was no significantly greater number of the HCM-
associated variants that would cause increase in the binding propensities of human troponins 
(Table 4.4). However, there were some proportional differences in binding propensities of 
variant proteins associated with HCM and DCM (Table 4.5).  
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Figure 4.2 Proportional differences among variants causing significant binding 
propensity changes in three different cases; no-disease, HCM-, and DCM-associated. ‘All 
Troponins’ (Troponin comples) combines counts for individual troponin components, TnC 
(Gene ID: TNNC1), TnT (Gene ID: TNNT2), and TnI (Gene ID: Gene ID TNNI3). 
 
Table 4.4 1-Tailed Fisher’s exact test p-values for binding propensity & HCM association. We 
tested the significance of the proportions of HCM-related variants possessing higher binding propensity 
than wild type proteins. 
 
Category MoRFpred ANCHOR DisoRDPbind 
Troponin complex 0.5249 0.08112 0.7605 
TnC 1 0.4126 0.7381 
TnT 0.2143 0.4843 0.8683 
TnI 1 0.3182 0.4783 
 
 
Variants leading to higher MoRFpred score have an association with greater number of 
diseases. However, ANCHOR, and DisoRDPbind show non-significant proportional differences 
between binding propensity directions in the troponin complex and in individual proteins with the 
exception of ANCHOR data for TnI, which showed relatively smaller p-value (~ 0.09). 
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Table 4.5 Goodness of fit test p-values to find association between binding propensity & both of 
disease types. We tested proportional differences between the mutations causing decrease or increase 
in disorder-based binding propensity in both types of disease (HCM & DCM). 
 
Category MoRFpred ANCHOR DisoRDPbind 
Troponin complex 3.61E-05 0.1573 0.4733 
TnC 0.008151 0.4054 0.5271 
TnT 0.03251 0.2498 0.6121 
TnI 0.01141 0.08808 0.8348 
 
 
4.2.3 Post-translational Modification (PTM) Changes 
 PTM site predictions showed some changes between the wild type of each troponin and 
its variants. At the high confidence level, there were seven amino acid substitutions in these 
proteins that affected predisposition of mutated residues for PTMs: D2G mutation in TnC 
created N-terminal acetylation site; in TnI, K58N mutation created amidation site, K183E 
mutation created carboxylation site, and S199N and K207R mutations created proteo- lytic 
cleavage sites; and in TnT, new ubiquitination and disulfide linkage sites were created by E33K 
and R278C mutations, respectively. At the medium confidence level, R147C mutation in TnC 
eliminated ADP-ribosylation site; in TnI, I195M and A157V mutations eliminated amidation sites, 
K174N mutation created N-linked glycosylation site, K193N mutation created proteolytic 
cleavage site, whereas R74S, R192C, R204H, and E209K mutations removed ADP- 
ribosylation sites; in TnT, acetylation site was removed by K273E mutation, proteolytic cleavage 
site was created by R134G mutation, R84S, R84T, and R286H mutations elimi- nated ADP 
ribosylation sites. Again, many of these mutations are found in a healthy population and 
therefore are not associated with heart diseases. 
From the viewpoint of the troponin complex, there were more chances of becoming 
highly scored PTM due to the sequence variations. In detail, only TnC showed a smaller number 
of mutated residues that became scored ‘High’ in PTM predictions, and a greater number of 
mutated residues with the decreased scores of PTM predictions. However, TnT, and TnI 
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showed the opposite trend. Two proteins showed a greater predicted number of PTMs and were 
scored ‘High’ in corresponding PTM predictions (Table 4.6). 
Table 4.6 Number of SNPs located within the 11-residue-window centered at PTM site and affected 
by disease-causing mutations. 
 
Category Becomes PTM with ‘High’ 
probability 
‘High’ PTM becomes less probable 
Troponin complex 113 49 
TnC 17 24 
TnT 60 8 
TnI 36 17 
 
To investigate the connectivity with the disease types (HCM and DCM), linear bar 
models of three proteins were constructed from the SNP point centered within the 11 amino 
acids' window (Figure 4.3). All three bar models for troponin proteins showed a greater number 
of disease- associated SNPs that became ‘High’ scored PTMs. Among three proteins, TnC 
showed relatively even distribution between HCM-, and DCM-associated SNPs. However, TnT 
showed the characteristic pattern, where there was an association of N-terminal SNP with HCM 
and C-terminal SNP with DCM. In TnI (Pinto et al., 2011), all of the disease- related SNPs were 
HCM-associated and were located at relatively far end of N- and C-termini. These observations 
suggest that TnC mutations do not affect the protein PTMs per se, but somehow they might 
hinder the TnC effect in other troponin subunits such as TnI (Pinto et al., 2011). In contrast, TnI 
and TnT mutations modulate the predisposition of these proteins for PTMs and affect their PTM 
status. 
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Figure 4.3 Disease-associated SNPs affecting PTM sites in various cardiac troponin 
components. Data are presented in C1N1C2 (C3N2) form, where C1 and C2 correspond to 
the wild type and mutant residue at position N1, and C3 and N2 show the identity and 
location of the residue PTM of which is affected by the C1N1C2 mutation. Colors are used to 
distinguish disease association types; red for HCM, blue for DCM. Direction of arrow in front 
of each SNP ID corresponds to the direction of the change induced by mutation in the 
strength of PTM prediction, which might increase (arrow up), or decrease (arrow down). Note 
that the majority of mutations have indirect effects on PTM sites. Asterisk is used to show 
locations of SNPs that directly affect PTM sites (i.e. where N1 = N2). 
 
4.3 Discussion 
Recent studies clearly indicated that not all biologically active proteins are structured, 
and that all proteomes studied so far contain numerous proteins that despite their lack of 
ordered structure possess numerous biological functions. Intrinsic disorder means 
conformational plasticity, which arms IDPs/IDPRs with a broad arsenal of means to be 
functionally superior and have numerous advantages over the functional modes of ordered 
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proteins and domains [182, 183]. For example, IDPs/IDPRs are very promiscuous binders that 
are constantly involved in various interactions with diverse partners, are known to play key roles 
in protein-protein interaction networks [190, 191]. They possess specific identification regions 
utilized for partner recognition and binding, as well as for regulation and control of signaling 
pathways [192, 193]. Various PTMs (such as phosphorylation, acetylation, methylation, 
lipidation, ubiquitination, sumoylation, etc.), which provide an efficient tool for the controllable 
modulation of biological functions, are known to be simplified in IDPs/IDPRs due to the high 
accessibility of their potential target sites [194-196]. Also, disorder is crucial for formation, 
regulation and function of various protein complexes [185, 197]. It was pointed out that in 
protein complexes, intrinsic disorder is used for several internal purposes, such as assembly, 
movement, and functional regulation of the different parts a given complex, and also has an 
important external use, defining the interaction of a complex with its external regulators [185]. 
Furthermore, it was emphasized that IDPs/IDPRs are commonly involved in the pathogenesis of 
numerous human diseases [28, 41, 198] and therefore should be considered as potential novel 
drug targets [50-52, 199]. In fact, disease-associated mutations were shown to disrupt 
functionally important regions of intrinsic protein disorder [35]. Based on these premises, we 
analyzed the peculiarities of disorder distribution within the TnC, TnT, and TnI involved in the 
formation of the cardiac troponin complex and studied the effects of HCM- or DCM-causing 
mutations on disorder predisposition of these proteins leading to changes in their binding 
propensity and predisposition for PTMs. 
Information about structural properties and disorder status of individual troponin chains 
is mostly limited to TnI, which was shown to have functionally important IDPRs [200-203]. 
Unfortunately, much less is currently known about prevalence of intrinsic disorder in TnC and 
TnT alone because of noticeable experimental restrictions. For example, the biggest challenge 
in studying TnT structure is that this protein is not soluble even in the presence of high salt 
concentrations and therefore cannot be easily analyzed by NMR. Also, high natural flexibility of 
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TnT (especially flexibility of the tail domain TnT1) precludes its crystallization, making the full-
length protein unavailable for structural studies. TnC is also very flexible, and most of the 
structures available for this protein were obtained in the presence of Ca2+ and Ca2+ sensitizer to 
stabilize the protein. Therefore, it seems that at the moment, the computational analysis similar 
to one conducted in our study represents a logical approach to answer the question on 
structural properties of these proteins. 
Our analyses also suggested that TnC, TnI, and TnT might have several PTM sites. In 
agreement with these predictions, an analysis of the cardiac TnI purified from human heart 
tissue using the top-down high-resolution tandem mass spectrometry in conjugation with 
immunoaffinity chromatography purification revealed a high degree of heterogeneity of this 
protein, with sample containing isoforms produced by phosphorylation, acetylation, oxidation, 
and C-terminal proteolysis [204]. Similar approach showed that cardiac TnI isolated from 
domestic pig hearts was phosphorylated and N-terminally acetylated [205] and that 
phosphorylation is conserved in human and mouse cardiac TnIs [206]. Even more impressively, 
high-resolution top-down Fourier transform ion cyclotron resonance (FT-ICR) MS analysis of the 
cardiac TnI sample purified from healthy human heart tissues revealed a total of thirty-six 
proteome forms resulting from acetylation, phosphorylation, oxidation and proteolytic 
degradation of this protein [207].  
Our analysis also shows that the HCM- and DCM-associated mutations in cardiac 
troponins affected the PTM maps of these proteins. This is an important observation which is in 
accord with current knowledge emphasizing that the phosphorylation sites in sarcomeric 
proteins are altered in cardiomyopathy and other heart diseases. For example, it has been 
shown that the efficiency of phosphorylation of cardiac TnI at 14 positions is noticeably altered 
in heart failure [208]. Here, the extents of phosphorylation at the protein kinase A sites (S22, 
S23) and sites located within the N-terminal cardiac extension of TnI (S4, S5, Y25) were 
noticeably decreased, whereas the extents of phosphorylation at the protein kinase C sites (S41, 
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S43, T142), and sites at the IT-arm domain (S76, T77) and C-terminal domain (S165, T180, 
S198) were significantly increased [208]. Also, an analysis of the HCM-associated mutations in 
cardiac TnI revealed that despite the fact that two such mutations, R21C and R146G, are 
located in TnI different regions, within the cardiac-specific N terminus and the inhibitory peptide, 
respectively, both of them reduced the efficiency of the TnI phosphorylation at the S23/S24 
position [209-211].  
4.4 Methods 
4.4.1 Intrinsic disorder and binding propensity change due to variations 
To measure significance of each variation’s intrinsic disorder and binding propensity 
change, sequences of three types of troponin subunits; TnC, TnT, and TnI are obtained from 
UniProt 2015_04 [212]. Their UniProt IDs (ENSEMBL transcript IDs) are P63316 
(ENST00000232975), P45379-6 (ENST00000367318), and P19429 (ENST00000344887), 
respectively. Then, each protein’s variant list was obtained from the database, ENSEMBL 
Release 79, and three previous research papers [177, 213-215]. In detail, the list of TnC was 
obtained from the ENSEMBL, and Kalyva et al. [177, 213], TnT variation list was obtained from 
Willott et al., and Alfares et al. [214, 215], and TnI variation list was obtained from the 
ENSEMBL, and Willot et al. [213, 214]. Based on the lists, variant sequences were prepared 
using Python 3 programming. 
All wild type and variant sequences were analyzed for intrinsic disorder propensity by 
three different algorithms, PONDR-FIT [62], PONDR-VSL2 [58, 59], and PONDR-VLXT [56, 57]. 
Binding propensities of these proteins were evaluated by three algorithms, MoRFpred, 
ANCHOR, and DisoRDPbind [216-219]. We also distinguished variants associated with HCM or 
DCM according to Willot et al. and Kalyva et al. [177, 214]. Although, Alfares et al. [215] 
described some HCM-associated variants, we did not assign HCM or DCM association based 
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on their research, because it only dealt with HCM, and there are some variants, which were 
known to be associated with DCM.  
To verify whether variants cause significant changes in the binding propensity, the 
corresponding per-residue scores of each variant were compared with the scores of the wild 
type protein using the Wilcoxon signed rank test. The 1-tailed test p-values were obtained 
through Python 3 programming and its modules, numpy and scipy, based on hypothesis 1 and 
2:  
H0: Variant score  ≤  Wild type score      (1) 
H1: Variant score  > Wild type score      (2) 
 
For the evaluation purposes, the hypothesis H0 was rejected if the corresponding p-value 
was less than alpha level of 0.05, and, therefore, the corresponding variant score was 
considered to be significantly greater than the score of the wild type protein. According to the 
statistics distribution, if p-value was greater than 0.95, it was understood as the variant score 
being significantly smaller than that of the wild type protein.  
Next, we verified whether the changes in the intrinsic disorder scores induced by the 
variants were significantly less than wild type in HCM cases (hypothesis 3-4). Thus, we 
established 2×2 contingency tables for all proteins (troponin complex). Since smaller intrinsic 
disorder scores within and IDPR could cause greater binding propensity, the 2×2 contingency 
tables for the analysis of changes in the binding propensity were constructed using hypothesis 5 
and 6. To verify the hypothesis below (3 - 6), we applied 1-tailed Fisher’s exact test using R 3.1. 
The results were evaluated based on the p-values at the alpha level of 0.05. 
 
For intrinsic disorder changes: 
H0: HCM-associated & significantly smaller intrinsic disordered case proportion ≤ DCM-
associated & significantly smaller intrinsic disordered case proportion  (3) 
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H1: HCM-associated & significantly smaller intrinsic disordered case proportion > DCM-
associated & significantly smaller intrinsic disordered case proportion  (4) 
 
For binding propensity changes: 
H0: HCM-associated & significantly greater binding propensity case proportion ≤ DCM-
associated & significantly greater intrinsic disordered case proportion  (5) 
H1: HCM-associated & significantly greater binding propensity case proportion > DCM-
associated & significantly greater intrinsic disordered case proportion  (6) 
      
To check whether there is a difference of the proportions of the smaller and greater 
score changes in both diseases without distinction of types, we applied Chi-square goodness of 
fit test using R 3.1 based on the hypotheses 7-10 below. The results were evaluated based on 
p-values, at alpha level of 0.05. 
 
For intrinsic disorder changes: 
H0: Significantly smaller intrinsic disordered case proportion = Significantly greater 
intrinsic disordered case proportion       (7) 
H1 : Significantly smaller intrinsic disordered case proportion ≠ Significantly greater 
intrinsic disordered case proportion       (8) 
 
For binding propensity changes: 
H0: Significantly smaller binding propensity case proportion = Significantly greater 
binding propensity case proportion       (9) 
H1: Significantly smaller binding propensity case proportion ≠ Significantly greater 
binding propensity case proportion       (10) 
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4.4.2 Post-translational modifications (PTM) change due to variations 
  The amino acid sequences of the wild type and mutant troponin proteins TnC, TnT, and 
TnI were used to predict their predispositions for the PTMs using ModPred Windows OS User-
interface version [196]. Then, the related propensities of each wild type residue were compared 
to those of corresponding mutated residue of each variant using the Python 3 programming. In 
this analysis, we used only high confidence cases; i.e., cases corresponding to the scenarios 
where mutations induced changes to or from ‘High’ confidence in a wild type protein. To 
investigate further, we focused on the cases where the positions were directly affected by 
mutations (SNPs). We also looked at the effect of SNPs on the protein regions containing PTMs 
using the SNP-centered window of 11 amino acids. 
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CHAPTER 5. PERSPECTIVES 
 
5.1 Discovery of Drugs Targeting Disorder-to-Order Transition Sites in Proteins  
 Scientists have discovered many drug leads targeting structurally defined regions such 
as enzyme active sites using so-called structure-based rational drug design through molecular 
docking as the technique started from the pioneer work of Stephen Cohen [66]. Although it 
represents a meaningful and very productive approach, and although a lot still can be done in 
the field of drug discovery that is focusing on the rigid regions of target proteins, the time is right 
to start seriously considering flexible (or intrinsically disordered) regions of proteins as novel and 
promising drug discovery targets. 
 Presented in this thesis, the MBD2-p66α inhibitor discovery study proved usefulness for 
the computer-aided drug discovery research that is focused on potentially foldable protein 
regions that undergo disorder-to-order transitions upon interaction with binding partners. As 
described in Chapter 2, this novel approach started with the comparison of MBD2 with Myc that 
contains a similar intrinsic disorder pattern in its binding region. Although the Myc disorder-to-
order transition inhibitor 10058-F4 was discovered in wet lab experiments using yeast as a 
model organism [98], we were able to find drug leads for compounds inhibiting the MBD2-p66α 
complex formation using a computational approach, namely molecular docking targeting the 
p66α region possessing an intrinsic disorder pattern similar to that of the Myc binding region. 
Furthermore, protein sites potentially engaged in binding of drug leads were further 
characterized through molecular dynamics simulations. 
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Although we did not define as of yet whether MBD2-inhibitor or p66α-inhibitor can cause 
structural changes in a target protein after binding, the previous work on the 10058-F4-Myc 
system showed that the binding regions of Myc undergoes a structural transition from the 
irregular to α-helical structure upon 10058-F4 binding [100]. The 10058-F4 Myc inhibition 
mechanism is considered as an entropy driven process [104]. This is a theoretically novel 
approach in the field of drug discovery, and, more importantly, we were able to find drug leads 
and evaluate the efficiency of their binding through purely computational research. 
 In the computation platform for discovery of drug leads targeting disorder-to-order 
transitions in proteins, the study starts with the intrinsic disorder prediction, followed by 
molecular docking and molecular dynamics simulation to find and evaluate the novel drug leads, 
respectively. Although the precise molecular mechanisms behind this approach should be 
further investigated, it opens a novel direction in the drug discovery field. 
5.2 Research Focused on Protein Intrinsic Disorder and Conformational Flexibility as a 
Novel Way of Solving Other Scientific Questions 
 The ALAS MD simulation study provided crucial information on potential molecular 
mechanism of the previously determined faster rate of the reaction catalyzed by the ALAS 
hepta-variant (Chapter 3). In this study, protein intrinsic disorder prediction played an important 
role in setting up a hypothesis that structural effects caused by seven simultaneous mutations in 
mouse ALAS occur at the active site loop of the hepta-variant. This analysis revealed that the 
mouse hepta-variant ALAS possessed less intrinsic disorder than the wild type protein. And the 
RMSF data derived from the MD simulations generated pattern supported this hypothesis on the 
restricted flexibility of the affected active site loop. Finally, it turned out that the hepta-variations 
cause a stretch of the loop to become a β-strand. 
 During this study, we found a very different RMSD pattern in hepta-variant chain A, 
which was distinct from that in other protomers. When more flexible regions (N-terminal helix, 
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and C-terminal tail) of each protomer were not considered during the backbone RMSD 
calculation, no meaningful difference was detected between the protomers in relation to their 
backbone RMSD trajectories. However, when the flexible regions are included in the backbone 
RMSD calculation, then RMSD of the chain A of the mALAS2 hepta-variant homodimer 
dramatically increased. Furthermore, we were able to find many representative structures of the 
mALAS2 hepta-variant chain A that possessed a novel β-strand (and not an irregular structure) 
at the affected active site loop region according to PCA-cluster analysis. However, similar 
patterns were not detected for the chain B of the hepta-variant homodimer. Therefore, our data 
suggested that seven simultaneous mutations caused prominent homodimer asymmetry in 
mouse ALAS, as it was discussed in Section 3.3.  
 Although the homodimer asymmetry is already known phenomenon, it is not yet clearly 
explained, as a natural mechanism to promote allostery [220]. However, if protein intrinsic 
disorder of flexible parts (such as, N-terminal helix or C-terminal tail) are considered, the 
homodimer asymmetry could be explained from the thermodynamics viewpoint. One should 
also keep in mind that we are not dealing with the allostery in the context of the MD simulations 
of substrate bound enzyme, since we observed the homodimer asymmetry in the absence of 
substrate; i.e., for the apo-ALAS homodimer. Dynamic properties of the N-terminal helix and C-
terminal tail were found through the backbone RMSD analysis. Since high structural flexibility 
correlates with high levels of intrinsic disorder, the flexible parts of the mALAS (its N-terminal 
helix and C-terminal tail that protrude outside of protein globule) are not characterized by the 
high levels of folding energy, but have high entropy moving in a wider space, thereby satisfying 
the second law of thermodynamics. However, since the active site loop is embedded within a 
narrow space between the ordered regions, its entropy is limited, and the loop might be 
characterized by greater folding energy, instead. 
This hypothesis could be supported if one could find a protein containing a structured 
region that is homologous to the disordered C-tail of mALAS. According to a small 
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bioinformatics study, I was able to find a bacterial protein (Phosphoribosyl-AMP cyclohydrolase 
from Methanothermobacter thermautotrophicus) containing a C-terminal tail characterized by 
high levels of predicted intrinsic disorder that was able to form two β-strands (see Figure 5.1). 
Obviously, this is just a starting point in a long journey aiming to search for an explanation of the 
energy contributions of flexible regions to the overall protein structure, and further investigations 
are needed to prove or disprove the validity of this hypothesis. 
 
 
Figure 5.1 mALAS2 C-terminal tail region similar structured protein [221]. A-B mALAS2 
Intrinsic disorder score, and its protomer MD simulation structure. C-D Methanothermobacter 
thermautotrophicus Phosphoribosyl-AMP cyclohydrolase intrinsic disorder score, and its 
structure PDB ID 1ZPS. Intrinsic disorder scores were measured using PONDR-VLXT, -VSL2, 
-FIT, and averages among those results (FX2). 
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5.3 Disease Causing Variant Research, and Personalized Medicine 
 Through cardiomyopathy study, we could derive previously unknown properties of the 
disease associated missense mutations of the cardiac troponin encoding genes: TNNC1, 
TNNT2, and TNNI3. Because all three proteins are expected to be highly disordered in their un-
bound forms and gain structure at the troponin complex formation, because of the cardiac 
muscle contraction is controlled by Ca2+ concentration, and because the troponin complex is 
serving as a Ca2+ sensor, we hypothesized that there could be a relation between the changes 
in the protein intrinsic disorder propensity  induced by mutations (i.e., the ability of 
corresponding mutations increase or decrease local levels of intrinsic disorder predisposition) 
and the disease type (HCM or DCM). However, this hypothesis was not supported by the results 
of our analysis. Instead, we found that both disease types (HCM and DCM) are significantly 
associated with mutations causing decrease in the local intrinsic disorder. Among several tools 
used to find how mutations would affect the predisposition of proteins for the disorder-based 
interaction, some meaningful results were generated by MoRFpred, since variants leading to 
higher MoRFpred score were shown to have an association with greater number of diseases. 
Finally, through the analysis of the effect of mutations on predicted PTM sites, we were able to 
generate a chart showing potential effects of mutations on the PTM distributions. 
 As the personalized medicine era is coming, people start to notice the importance of 
their genome information. Nowadays, only 14 years since the completion of the Human 
Genome Project, some companies started to provide genome analysis service to customers. 
Obviously, many genetic factors are related to diseases, and this fact serves as a background of 
ever increasing application of genome bioinformatics for diagnosis. However, accurate 
diagnosis is not the final goal of modern medicine. The better understanding of molecular 
mechanisms is crucial for finding efficient treatments of different maladies. This emphasizes the 
importance and necessity of pharmacogenomics. People have about ~3 million variations in 
their genome on average [222-224]. Some of those cause diseases, but many other mutations 
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do not. Furthermore, some genome variations can be associated with enhanced probability of 
side effects or insensitivity toward drugs among treated patients. To investigate such differences 
in the outputs of genomic variations at molecular level, bioinformatics is absolutely crucial and 
should be utilized not only for the improvement of diagnosis, but also for finding new way of 
treatment. 
 Computational evaluation of protein intrinsic disorder could serve as a starting point in 
pharmacogenomics. Similar to the situation with troponin genes described in this work, there are 
numerous disease-associated genetic variations in various pathology-related proteins. Through 
the careful analysis of the outputs of intrinsic disorder predictions, we could find a connection 
between the effects of mutations on protein structure and function, and disease. From this 
viewpoint, protein intrinsic disorder has a great potential to help approaching the final purpose, 
better human health in personalized medicine era. 
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A Targeting Small Molecule Inhibitor of MBD2-p66α Interaction Induces 
Myeloid Leukemia Cell-specific Cell Death
Chul Geun Kim 1 ; Min Young Kim 1 ; Insung Na 2 ; Young Su Lim 1 ; Ji Sook Kim 1 ; Yu Chen 2 ; Arjan van der Vaart 2 ; Eun Jung Baek 4 ; Young Yeol Lee 3 ; Buom-
Yong Ryu 5 ; Vladimir N. Uversky 2 
1) Hanyang University, Seoul, KR; 2) University of South Florida. Tampa, USA; 3) Hanyang University College of Medicine, Seoul, KR; 4) Hanyang University College of 
Medicine, Guri-si, KR; 5) Chung-Ang University, Ansung, KR. 
Mi-2/NuRD (Nucleosome Remodeling and Deacetylase) chromatin remodeling complex (CRC), an assemblage of
proteins that combine key epigenetic regulators necessary for histone deacetylation and demethylation, is known
to be an epigenetic reader of DNA methylation that regulates genes involved in normal development and
neoplastic diseases. To our surprise, we have found that MBD2 and MBD3 are downregulated, with no disruption
of the integrity of the Mi-2/NuRD complex, during terminal differentiation of MEL cells in vitro as well as normal
erythropoiesis in the bone marrow. In further, we confirmed that MBD2 downregulation potentiates terminal
erythroid differentiation and transcriptional activation of both α- and β-globin genes via recruitment of TFCP2
(CP2c) TF complexes to their promoters. In accordance with the previous report that MBD2 recruits the CHD4
nucleosome remodeling protein to the complex via a coiled-coil interaction with GATAD2A (p66α), spontaneous
differentiation of MEL cells occurred by arbitral disruption of MBD2-p66α interaction or MBD2 knock down. Along
with previous report that MBD2 knock out mice are viable and fertile, our data indicate that MBD2-p66α
interaction is involved in gene silencing in general, but is dispensable in normal differentiation of some types of
cells, i.e., erythroid lineage cells and also strongly suggest that disruption of MBD2-p66α interaction induces
normal differentiation or cell death of some types of leukemia, like MEL cells which are arrested at the
proerythroid stage. Based on this, we identified small molecules disrupting MBD2-p66α interaction using a
computer aided molecular docking and tested their usefulness as an anticancer drug in various available cancer
cell lines. We found that a drug 086567 shows a specific anticancer effect to myeloid leukemia cells with IC50 =
~20 μM, and also confirmed its anticancer effect in the mouse xenograft model of MEL cells. Mechanistically, this
drug causes cell cycle arrest at various stages, leading to chromosomal aneuploidy and apoptotic gene
expression.
The Allied Genetics Conference 2016 (TAGC 2016) in Orlando, Florida, 13-17 July 2016
ABSTRACT BACKGROUND
AIMS
RESULTS
Down-regulation of MBD2/MBD3 expression is crucial for 
terminal erythropoiesis in vitro and in vivo
CONCLUSIONS
MBD2-p66α interaction is crucial for Mi-2/NuRD complex assembly and 
necessary for MBD2-mediated gene silencing in vivo
Hypothesis: MBD2 might be a good
target for anticancer drugs.
• Identify small molecules that inhibit the interaction between MBD2 and p66α and 
validate their significance as a anticancer drug.
Identification of Candidate Small Molecules that Inhibit the 
Interaction between MBD2 and p66α
Fig. 1. Experimental 
Scheme
Fig. 2. MBD2-p66α inhibitor ligand discovery
(Aand B) Intrinsic disorder score similarity between MBD2 and Myc
(C-E) Molecular docking results of two MBD2-p66α targeted
candidates and Myc targeted drug (10058-F4)
Fig. 3. Contact number analysis on three
50ns MD simulations
(A ) Chronological contact number variations. (B)
Average number of contacts. (C)
(Normalized contact number of each residue
Fig. 4. MBD2-p66α inhibitor ligand 
evaluation through molecular dynamics 
simulation
(A ) Backbone root-mean squared fluctuations (RMSF). 
(B-E) Ramachandran plots of binding residues at four 
MD simulation results
Candidate Small Molecules Were Confirmed to Inhibit the Interaction 
between MBD2 and p66α with different modes of action
Fig. 5. Evaluation  of candidates on the inhibition of MBD2-p66α interaction and Mi-2-NuRD CRC function.
(A ) Names and structures of candidates. (B-C) Co-IPs showing effects on the MBD2-p66α interaction.  (D-E) Luc reporter assays showing 
effects on the Mi-2/NuRD CRC function.
Candidate Small Molecules may Inhibit 
Cancer Cell Metastasis
Fig. 6. Candidates’ effects on migration and invasion of 
cancer cells in vitro.
(A-B ) Effects on cancer cell migration. 
(C-D) Effects on cancer cell invasion.
ZINC40430779 ( #086567, Fluorochem) shows a specific anticancer effect to 
myeloid leukemia cells 
Fig. 7. Evaluation of anticancer effects in cancer
cell lines with various origins in vitro.
(A) Summary on IC50 values. (B-D) Cell proliferation assays,
growth inhibition curves with IC50 values, and photographs of cells
in several representative cancer samples, respectively.
Fig. 8. Evaluation of ZINC40430779 (#086567,
Fluorochem) anticancer effect in mouse
xenograft model.
(A -E) Evaluation of cancer cell survival effect. (F-J) Evaluation of
therapeutic effect.
Our computer-aided platform using molecular docking and  
molecular dynamics simulation to the disorder-to-order transition 
site important for  protein-protein interaction might be a valuable 
tool to identify and evaluate novel small molecules.
Two small molecules inhibiting the MBD2-p66α interaction  in the Mi-
2/NuRD CRC show efficient anti-metastasis effects in cancer cells 
with different origins
ZINC40430779 ( #086567, Fluorochem) also shows a novel anti-
myeloid leukemia effect.
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Fig. 9. ZINC40430779 ( #086567, Fluorochem)
inhibits cell cycle progression and induces
apoptosis in myeloid leukemia cells.
(A -D) Cell cycle analyses by FACs and western blots. (E) Western
blots showing apoptosis-related marker expression
 
 
 
APPENDIX B: A TARGETING SMALL MOLECULE INHIBITOR OF MBD2-P66Α 
INTERACTION INDUCES MYELOID LEUKEMIA CELL-SPECIFIC CELL DEATH 
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APPENDIX C: MOLECULAR DYNAMICS ANALYSIS OF STRUCTURAL AND DYNAMIC 
PROPERTIES OF THE FUNCTIONALLY ENHANCED HEPTA-VARIANT OF MOUSE 5-
AMINOLEVULINATE SYNTHASE 
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APPENDIX D: TROPONINS, INTRINSIC DISORDER, AND CARDIOMYOPATHY 
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